Anti-LILRB1 antibodies and uses thereof
By developing anti-LILRB1 antibodies that can block the binding of LILRB1 to MHC class I, the problem of immune escape by cancer cells is solved, the ability of immune cells to attack cancer cells is significantly improved, and the effective anti-cancer effect is achieved.
Patent Information
- Application Number
- CN202080087379.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-22
- Filing Date
- 2020-12-22
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-12-22
AI Technical Summary
The prior art is difficult to effectively block the binding of LILRB1 and MHC class I, resulting in immune escape from cancer cells and lack effective anti-cancer treatment methods.
An anti-LILRB1 antibody or its antigen-binding fragment was developed, which can block the binding of LILRB1 to MHC class I, inhibit the immune escape of cancer cells, and have anti-cancer effects. The antibody contains a specific complementary determining region (CDR) sequence that reverts the activity of immune cells by binding to LILRB1, interfering with its interaction with MHC class I.
By inhibiting the immune escape mechanism of cancer cells, the ability of immune cells to identify and attack cancer cells is significantly improved, and it demonstrates an efficient anti-cancer effect, which can target cancer cells that express or overexpress MHC class I.
Smart Images

Figure CN114945594B_ABST
Abstract
Description
Technical Field
[0001] Cross-references to related applications
[0002] This application claims the rights to KR 10-2019-0173414 filed with the Korean Intellectual Property Office on December 23, 2019 and KR 10-2020-0061907 filed on May 22, 2020, the entire disclosure of which is incorporated herein by reference.
[0003] This disclosure relates to an anti-LILRB1 antibody and its use. More specifically, it provides an anti-LILRB1 antibody or an antigen-binding fragment thereof, and its use in cancer treatment. Background Technology
[0004] Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1; also known as ILT2, CD85j, or LIR-1) is an inhibitory receptor expressed in cells such as B cells, T cells, NK cells, dendritic cells, macrophages, and other immune cells. LILRB1 participates in signal transduction mechanisms that inhibit immune cell activity by binding to both classical and non-classical MHC class I receptors.
[0005] Meanwhile, it has been reported that various cancer cells overexpress MHC class I cells such as HLA-G to evade the immune system. It is anticipated that blocking the binding of LILRB1 to MHC class I cells would allow the restoration of suppressed immune cell activity, thereby exhibiting an anti-cancer effect.
[0006] Therefore, there is a need to develop novel agents that bind to LILRB1 and block the binding of LILRB1 to MHC class I and / or the interaction between LILRB1 and MHC class I. Summary of the Invention
[0007] Technical issues
[0008] This disclosure provides antibodies that bind to LILRB1, act on LILRB1-expressing immune cells, regulate the activity of immune cells, and exhibit anticancer effects, as well as their use in cancer treatment.
[0009] One embodiment provides an anti-LILRB1 antibody or its antigen-binding fragment that binds to LILRB1. The anti-LILRB1 antibody or its antigen-binding fragment may have activity that blocks the binding of LILRB1 to MHC class I and / or blocks the interaction between LILRB1 and MHC class I. Additionally, the anti-LILRB1 antibody or its antigen-binding fragment may have activity that inhibits immune escape from cancer cells. Furthermore, the anti-LILRB1 antibody or its antigen-binding fragment may have anti-cancer activity. This anti-cancer activity may target cancer cells that express or overexpress MHC class I on their cell surface.
[0010] Another embodiment provides a pharmaceutical composition for treating and / or preventing cancer, the composition comprising an anti-LILRB1 antibody or an antigen-binding fragment thereof as an active ingredient.
[0011] Another embodiment provides a pharmaceutical composition for inhibiting the binding of LILRB1 to MHC class I and / or blocking the interaction between LILRB1 and MHC class I, said composition comprising an anti-LILRB1 antibody or its antigen-binding fragment as an active ingredient.
[0012] Another embodiment provides a pharmaceutical composition for inhibiting immune escape from cancer cells, the composition comprising an anti-LILRB1 antibody or an antigen-binding fragment thereof as an active ingredient.
[0013] [Technical Solution]
[0014] One embodiment provides an anti-LILRB1 antibody or its antigen-binding fragment that binds to LILRB1. The anti-LILRB1 antibody or its antigen-binding fragment may have activity that blocks the binding of LILRB1 to MHC class I and / or blocks the interaction between LILRB1 and MHC class I. Additionally, the anti-LILRB1 antibody or its antigen-binding fragment may have activity that inhibits immune escape from cancer cells. Furthermore, the anti-LILRB1 antibody or its antigen-binding fragment may have anti-cancer activity.
[0015] The anti-LILRB1 antibody or its antigen-binding fragment may include the following complementarity-determining regions (CDRs):
[0016] (1) Based on the definition of CDR according to Kabat number (Kabat, EA, Wu, TT, Perry, H., Gottesman, K. and Foeller, C. (1991) Sequences of Proteins of Immunological Interest, 5th edition. NIH Publication No. 91-3242; http: / / www.abysis.org / ),
[0017] CDR-L1, which contains the amino acid sequence of SEQ ID NO: 1, 7, 13, 19, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79, 85, 91, 97, 103, 109, or 115.
[0018] CDR-L2, which contains the amino acid sequence of SEQ ID NO:2, 8, 14, 20, 26, 32, 38, 44, 50, 56, 62, 68, 74, 80, 86, 92, 98, 104, 110, or 116.
[0019] CDR-L3, which contains the amino acid sequence of SEQ ID NO:3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, 81, 87, 93, 99, 105, 111, or 117.
[0020] CDR-H1, which contains the amino acid sequence of SEQ ID NO:4, 10, 16, 22, 28, 34, 40, 46, 52, 58, 64, 70, 76, 82, 88, 94, 100, 106, 112 or 118.
[0021] CDR-H2, comprising the amino acid sequence of SEQ ID NO: 5, 11, 17, 23, 29, 35, 41, 47, 53, 59, 65, 71, 77, 83, 89, 95, 101, 107, 113, or 119, and
[0022] CDR-H3, comprising the amino acid sequence SEQ ID NO: 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 96, 102, 108, 114, or 120; or
[0023] (2) Based on the CDR definition according to the IMGT number (http: / / www.imgt.org / ),
[0024] CDR-L1, which contains the amino acid sequence SEQ ID NO: 121, 126, 131, 136, 141, 146, 151, 156, 161, 166, 171, 176, 181, 186, 191, 196, 201, 206, 211, or 216.
[0025] CDR-L2, which contains the amino acid sequence SEQ ID NO: 122, 127, 132, 137, 142, 147, 152, 157, 162, 167, 172, 177, 182, 187, 192, 197, 202, 207, 212, or 217.
[0026] CDR-L3, which contains the amino acid sequence of SEQ ID NO:3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, 81, 87, 93, 99, 105, 111, or 117.
[0027] CDR-H1, which contains the amino acid sequence SEQ ID NO: 123, 128, 133, 138, 143, 148, 153, 158, 163, 168, 173, 178, 183, 188, 193, 198, 203, 208, 213, or 218.
[0028] CDR-H2, comprising the amino acid sequence SEQ ID NO: 124, 129, 134, 139, 144, 149, 154, 159, 164, 169, 174, 179, 184, 189, 194, 199, 204, 209, 214 or 219, and
[0029] CDR-H3, which contains the amino acid sequence of SEQ ID NO: 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215 or 220.
[0030] In one specific embodiment, a combination of six CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) that may be included in the anti-LILRB1 antibody or its antigen-binding fragment provided in this disclosure is shown in Table 1:
[0031] Table 1
[0032]
[0033]
[0034]
[0035] In one embodiment, the anti-LILRB1 antibody or its antigen-binding fragment may comprise:
[0036] Includes light chain variable regions of CDR-L1, CDR-L2, and CDR-L3, and
[0037] Heavy chain variable regions including CDR-H1, CDR-H2, and CDR-H3
[0038] The CDR is as described above.
[0039] More specifically, the anti-LILRB1 antibody or its antigen-binding fragment may comprise:
[0040] The light chain variable region comprises the amino acid sequence of SEQ ID NO: 221, 223, 225, 227, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259 or 345, and
[0041] The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258 or 260.
[0042] In one specific embodiment, combinations of light chain variable regions and heavy chain variable regions that may be included in the anti-LILRB1 antibody or its antigen-binding fragment provided in this disclosure are shown in Table 2:
[0043] Table 2
[0044]
[0045]
[0046]
[0047] In this disclosure, the expression “an antibody or antigen-binding fragment (e.g., CDR, variable region, or heavy / light chain) comprising, consisting of, or represented by a specific amino acid sequence” can refer to an antigen-binding fragment substantially consisting of: (1) the specific amino acid sequence or (2) an amino acid sequence in which a non-significant mutation (e.g., substitution, deletion, and / or addition of amino acid residues; resulting in no effect on antibody activity) is introduced into the amino acid sequence (1).
[0048] When measured by surface plasmon resonance (SPR), the anti-LILRB1 antibody or its antigen-binding fragment provided in this disclosure may have a concentration of less than 10 mM, less than 5 mM, less than 1 mM, less than 0.5 mM, less than 0.2 mM, or less than 0.15 mM, for example, 0.001 nM to 10 mM, 0.005 nM to 10 mM, 0.01 nM to 10 mM, 0.05 nM to 10 mM, 0.1 nM to 10 mM, 0 0.5nM to 10mM, 1nM to 10mM, 0.001nM to 5mM, 0.005nM to 5mM, 0.01nM to 5mM, 0.05nM to 5mM, 0.1nM to 5mM, 0.5nM to 5mM, 1nM to 5mM, 0.001nM to 1mM, 0.005nM to 1mM, 0.01nM to 1mM, 0.05nM to 1mM, 0.1nM to 1mM, 0.5nM to 1 mM, 1 nM to 1 mM, 0.001 nM to 0.5 mM, 0.005 nM to 0.5 mM, 0.01 nM to 0.5 mM, 0.05 nM to 0.5 mM, 0.1 nM to 0.5 mM, 0.5 nM to 0.5 mM, 1 nM to 0.5 mM, 0.001 nM to 0.2 mM, 0.005 nM to 0.2 mM, 0.01 nM to 0.2 mM, 0.05 nM to 0.2 mM, 0 Binding affinity (K0.1) to LILRB1 (e.g., human LILRB1) at concentrations of 0.1 nM to 0.2 mM, 0.5 nM to 0.2 mM, 1 nM to 0.2 mM, 0.001 nM to 0.15 mM, 0.005 nM to 0.15 mM, 0.01 nM to 0.15 mM, 0.05 nM to 0.15 mM, 0.1 nM to 0.15 mM, 0.5 nM to 0.15 mM, or 1 nM to 0.15 mM. D ).
[0049] Another embodiment provides a pharmaceutical composition comprising an anti-LILRB1 antibody or an antigen-binding fragment thereof as an active ingredient. For example, the pharmaceutical composition may be a pharmaceutical composition for treating and / or preventing cancer. The pharmaceutical composition may have activity that inhibits the binding of LILRB1 to MHC class I and / or the interaction between LILRB1 and MHC class I. The cancer may be a cancer associated with the interaction between LILRB1 and MHC class I. In one embodiment, the pharmaceutical composition may have activity that inhibits immune escape from cancer cells. The cancer cells may be cells that express or overexpress MHC class I on their cell surface.
[0050] Another embodiment provides a composition for blocking the binding of LILRB1 to MHC class I and / or the interaction between LILRB1 and MHC class I, said composition comprising an anti-LILRB1 antibody or its antigen-binding fragment as an active ingredient.
[0051] Another embodiment provides a composition for inhibiting immune escape from cancer cells, the composition comprising an anti-LILRB1 antibody or an antigen-binding fragment thereof as an active ingredient.
[0052] Another embodiment provides a method for treating and / or preventing cancer, the method comprising administering (orally or parenterally) a pharmaceutically effective amount of an anti-LILRB1 antibody or an antigen-binding fragment thereof to a subject (e.g., a mammal, including a human) who requires treatment and / or prevention of cancer.
[0053] Another embodiment provides a method for blocking the binding of LILRB1 to MHC class I and / or a method for blocking the interaction between LILRB1 and MHC class I, the method comprising administering (orally or parenterally) a pharmaceutically effective amount of an anti-LILRB1 antibody or its antigen-binding fragment to a subject (e.g., a mammal, including a human) who requires inhibition of the binding of LILRB1 to MHC class I and / or the interaction between LILRB1 and MHC class I.
[0054] Another implementation provides a method for inhibiting immune escape from cancer cells, the method comprising administering (orally or parenterally) a pharmaceutically effective amount of an anti-LILR1 antibody or an antigen-binding fragment thereof to a subject (e.g., a mammal, including a human) who requires inhibition of immune escape from cancer cells.
[0055] The methods provided in this disclosure may also include, prior to the administration step, identifying a subject who requires treatment and / or prevention of cancer, inhibition of LILRB1 binding to MHC class I and / or interaction between LILRB1 and MHC class I, and / or inhibition of immune escape from cancer cells.
[0056] Another embodiment provides a nucleic acid molecule (polynucleotide) encoding at least one polypeptide selected from the CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, CDR-H3, combinations of CDR-L1, CDR-L2 and CDR-L3 or combinations of CDR-H1, CDR-H2 and CDR-H3) of the anti-LILRB1 antibody described above, comprising light chain variable regions of CDR-L1, CDR-L2 and CDR-L3, and heavy chain variable regions of CDR-H1, CDR-H2 and CDR-H3; a light chain comprising the light chain variable regions, and a heavy chain comprising the heavy chain variable regions.
[0057] Another embodiment provides a recombinant vector containing the nucleic acid molecule. In one embodiment, the recombinant vector may, separately (e.g., in two separate vectors) or all together (e.g., in one vector), contain a nucleic acid molecule encoding a light chain variable region or light chain and a nucleic acid molecule encoding a heavy chain variable region or heavy chain. The recombinant vector can be used as an expression vector.
[0058] Another embodiment provides a recombinant cell comprising the nucleic acid molecule or the recombinant vector.
[0059] Another embodiment provides a method for preparing an anti-LILRB1 antibody or an antigen-binding fragment thereof, the method comprising expressing a nucleic acid molecule in cells. The step of expressing the nucleic acid molecule may include culturing recombinant cells.
[0060] As described herein, the antigen-binding fragment of an anti-LILRB1 antibody can refer to a fragment derived from the anti-LILRB1 antibody and retaining the antigen (LILRB1) binding affinity of said antibody. In one embodiment, the antigen-binding fragment can be a polypeptide comprising the six CDRs of the anti-LILRB1 antibody as described above, and can be, for example, scFv, scFv-Fc, scFv-Ck (κ constant region), scFv-Cλ (λ constant region), (scFv)2, Fab, Fab', or F(ab')2, but is not limited thereto. In one embodiment, the antigen-binding fragment can be scFv; wherein scFv is fused to the Fc region of an immunoglobulin (e.g., IgA, IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4), IgM, etc.) in a fusion polypeptide (scFv-Fc); or wherein scFv is fused to the constant region (e.g., κ or λ) of a light chain in a fusion polypeptide (scFv-Ck or scFv-Cλ).
[0061] The anti-LILRB1 antibody or its antigen-binding fragment may have regulatory activity on the LILRB1 protein, such as antagonistic or agonistic activity. Additionally, the anti-LILRB1 antibody or its antigen-binding fragment may have activity that blocks the binding of LILRB1 to MHC class I and / or the interaction between LILRB1 and MHC class I. Furthermore, the anti-LILRB1 antibody or its antigen-binding fragment may have activity that inhibits immune escape from cancer cells. Moreover, the anti-LILRB1 antibody or its antigen-binding fragment may have anti-cancer activity.
[0062] The protein LILRB1, which serves as the antigen of the anti-LILRB1 antibody or its antigen-binding fragment provided in this disclosure, can be derived from mammals. For example, the LILRB1 antigen can be human LILRB1 (e.g., GenBank accession number AAH15731.1 (SEQ ID NO:348), NP_001265328.2, NP_001265327.2, NP_001075108.2, NP_001075107.2, NP_001075106.2, NP_006660.4, NM_001081637.2, NM_001081638.3, NM_001081639.3, NM_001278398.2, NM_001278399.2, etc.), but is not limited thereto.
[0063] MHC class I can be a class of major histocompatibility complex (MHC) molecules. In one embodiment, the MHC class I can be human MHC class I and can be at least one selected from HLA (human leukocyte antigen)-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G, but is not limited thereto.
[0064] As described herein, the term "antibody" can refer to a protein that specifically binds to a particular antigen, and can be a protein produced by antigen stimulation in the immune system, or a protein produced through chemical synthesis or recombination, without specific limitations. Antibodies can be non-natural, for example, produced through recombination or synthesis. Antibodies can be animal antibodies (e.g., mouse antibodies), chimeric antibodies, humanized antibodies, or human antibodies. Antibodies can be monoclonal or polyclonal antibodies.
[0065] In the anti-LILRB1 antibody or its antigen-binding fragment provided herein, the portion other than the heavy chain CDR and light chain CDR portions or the heavy chain variable region and light chain variable region as defined above may be derived from any subtype of immunoglobulin (e.g., IgA, IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4), IgM, etc.), and for example derived from the framework portion and / or the light chain constant region and / or the heavy chain constant region. In one embodiment, the anti-LILRB1 antibody provided herein may be an antibody in the form of human IgG, such as IgG1, IgG2, IgG3, or IgG4, but is not limited thereto.
[0066] Intact antibodies (e.g., IgG type) have a structure containing two full-length light chains and two full-length heavy chains, with each light chain linked to a corresponding heavy chain via disulfide bonds. The constant regions of an antibody are divided into heavy chain constant regions and light chain constant regions. Heavy chain constant regions are of the γ, μ, α, δ, or ε type, and have γ1, γ2, γ3, γ4, α1, or α2 as subclasses. Light chain constant regions are of the κ or λ type.
[0067] As used herein, the term "heavy chain" may be intended to encompass full-length heavy chains and fragments thereof, wherein the full-length heavy chain may comprise a variable region VH (including an amino acid sequence sufficient to provide specificity for an antigen), three constant regions CH1, CH2, and CH3, and a hinge. The term "light chain" may be intended to encompass full-length light chains and fragments thereof, wherein the full-length light chain may comprise a variable region VL (including an amino acid sequence sufficient to provide specificity for an antigen), and a constant region CL.
[0068] The term "complementarity-determining region (CDR)" can refer to a portion of the variable region of an antibody that confers antigen-binding specificity, and can refer to an amino acid sequence found in the highly variable region of the heavy or light chain of an immunoglobulin. The heavy and light chains may each comprise three CDRs (CDRH1, CDRH2, and CDRH3; and CDRL1, CDRL2, and CDRL3). The CDRs can provide contact residues that play an important role in the binding of the antibody to its antigen or antigenic epitope. As used herein, the terms "specific binding" and "specific recognition" can have the same general meaning as known to those skilled in the art and indicate that the antibody and antigen specifically interact with each other to result in an immune response.
[0069] In this disclosure, unless otherwise stated, the term "antibody" may cover not only the complete antibody but also the antigen-binding fragment of an antibody that has antigen-binding ability.
[0070] As used herein, the term "antigen-binding fragment" can refer to any type of polypeptide containing a portion capable of binding to an antigen (e.g., the six CDRs described herein), and can be, for example, scFv, (scFv)2, scFv-Fc, Fab, Fab′, or F(ab′)2, but is not limited thereto. Additionally, as mentioned above, the antigen-binding fragment can be scFv, wherein the scFv is a fusion polypeptide fused to the Fc region or constant region (e.g., κ or λ) of an immunoglobulin (e.g., IgA, IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4), IgM, etc.).
[0071] In the antigen-binding fragment, Fab includes variable regions of the light and heavy chains, a constant region of the light chain, and a constant region of the first heavy chain CH1.
[0072] The difference between Fab' and Fab is that Fab' contains a hinge region having at least one cysteine residue at the C-terminus of CH1.
[0073] F(ab')2 antibodies are formed through disulfide bonds bridging cysteine residues in the Fab' hinge region.
[0074] Fv is the smallest antibody fragment consisting only of heavy chain variable regions and light chain variable regions. Recombinant techniques for generating Fv fragments are well known in the art.
[0075] Double-chain Fvs contain heavy-chain and light-chain variable regions linked together by non-covalent bonds. Single-chain Fvs typically contain heavy-chain and light-chain variable regions that are covalently linked together at the C-terminus via peptide linkers or directly linked to each other to have a dimer structure similar to that of double-chain Fvs.
[0076] Antigen-binding fragments can be obtained using proteases (e.g., Fab can be obtained by restrictive cleavage of the whole antibody with papain, and the F(ab′)2 fragment can be obtained by cleavage with pepsin), or they can be prepared using gene recombination technology.
[0077] The term "hinge region" can refer to the region between the CH1 and CH2 domains within the antibody heavy chain, which functions to provide flexibility for the antigen-binding site in the antibody.
[0078] Anti-LILRB1 antibodies can be monoclonal or polyclonal, and are, for example, monoclonal antibodies. Monoclonal antibodies can be prepared using methods well-known in the art, such as phage display technology. Alternatively, anti-LILRB1 antibodies can be constructed using conventional methods in the form of mouse-derived monoclonal antibodies.
[0079] Simultaneously, based on their binding potential to LILRB1, individual monoclonal antibodies can be screened using typical ELISA (enzyme-linked immunosorbent assay) formats. Inhibitory activity can be verified through functional analyses (e.g., competitive ELISA for verifying molecular interactions of the binding components) or cell-based assays. Then, for monoclonal antibody members selected based on their strong inhibitory activity, their affinity (Kd value) for LILRB1 can be individually verified.
[0080] In addition to the active ingredient (anti-LILRB1 antibody or its antigen-binding fragment), the pharmaceutical composition may also contain a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be any carrier commonly used in antibody preparations. For example, a pharmaceutically acceptable carrier may be one or more selected from lactose, dextran, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylparaben, propylparaben, talc, magnesium stearate, mineral oil, etc., but is not limited thereto. The pharmaceutical composition may also contain one or more selected from diluents, excipients, lubricants, wetting agents, sweeteners, flavor enhancers, emulsifiers, suspending agents, preservatives, etc., commonly used in the manufacture of pharmaceutical compositions.
[0081] The pharmaceutical composition or the antibody or its antigen-binding fragment may be administered orally or parenterally in a pharmaceutically effective amount. Parenteral administration may be via intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal application, intranasal application, intrapulmonary application, rectal application, or local application to the lesion. Since proteins or peptides are digested upon oral administration, the active ingredient in the composition for oral administration may be coated or formulated to prevent digestion in the stomach. Additionally, the antibody or the composition may be administered using an optional device capable of delivering the active ingredient to target cells (e.g., cancer cells).
[0082] The anti-LILRB1 antibody or its antigen-binding fragment may be included in the pharmaceutical composition or administered to the subject in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" can refer to the amount of active ingredient (antibody or fragment thereof) that enables the active ingredient (antibody or fragment thereof) to exert its desired effect (e.g., anticancer effect). Pharmaceutically effective amounts can be specified in various ways, depending on factors such as the subject's age, weight, sex, pathological condition, diet, excretion rate and / or responsiveness, type of formulation, time of administration, administration interval, route of administration, and manner of administration. For example, anti-LILRB1 antibody or its antigen-binding fragment can be administered daily at doses ranging from 0.005 ug / kg to 1000 mg / kg, 0.005 ug / kg to 500 mg / kg, 0.005 ug / kg to 250 mg / kg, 0.005 ug / kg to 100 mg / kg, 0.005 ug / kg to 75 mg / kg, 0.005 ug / kg to 50 mg / kg, 0.01 ug / kg to 1000 mg / kg, 0.01 ug / kg to 50 ... The dosage may be applied in amounts ranging from 0.01 ug / kg to 250 mg / kg, 0.01 ug / kg to 100 mg / kg, 0.01 ug / kg to 75 mg / kg, 0.01 ug / kg to 50 mg / kg, 0.05 ug / kg to 1000 mg / kg, 0.05 ug / kg to 500 mg / kg, 0.05 ug / kg to 250 mg / kg, 0.05 ug / kg to 100 mg / kg, 0.05 ug / kg to 75 mg / kg, or 0.05 ug / kg to 50 mg / kg, but is not limited to these. The daily dose may be formulated as a single unit or as appropriately separated dosage forms, or it may be manufactured in a multi-dose container.
[0083] The pharmaceutical composition may be formulated as a solution, suspension, syrup, emulsion, extract, powder, granule, tablet or capsule in an oil or aqueous medium, and may also contain a dispersant or stabilizer for formulation.
[0084] Subjects using the antibodies, pharmaceutical compositions or methods provided in this disclosure may be selected from mammals, including primates such as humans and monkeys, rodents such as rats and mice, etc.
[0085] Cancer can be a solid tumor or a blood cancer. Cancer can be, but is not limited to, one or more of the following: lung cancer (e.g., squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma), peritoneal cancer, skin cancer, squamous cell carcinoma, melanoma of the skin or eye, rectal cancer, cancer near the anus, esophageal cancer, small bowel tumors, endocrine gland cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, leukemia (e.g., chronic or acute leukemia), lymphocytic lymphoma, liver cancer, stomach cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatocellular adenoma, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland tumors, renal cell carcinoma, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, head and neck cancer, brain cancer, biliary tract cancer, gallbladder cancer, and osteosarcoma of the bone. Cancer can be primary or metastatic. Cancer can be characterized by the expression or overexpression of MHC class I on the surface of cancer cells, and can be, for example, colon adenocarcinoma, small cell lung cancer, breast cancer, pancreatic cancer, malignant melanoma, osteosarcoma of bone, renal cell carcinoma, or gastric cancer. Overexpression of MHC class I can refer to overexpression compared to normal cells or cancer cells that are unresponsive to or resistant to immunotherapy, such as T cell-mediated immunotherapy (e.g., cytotoxic T cell-mediated immunotherapy).
[0086] As used in this article, the term "cancer treatment" can refer to all anti-cancer effects that prevent, alleviate or improve cancer symptoms or partially or completely eliminate cancer, such as cancer cell death, inhibition of cancer cell proliferation, and inhibition of cancer metastasis.
[0087] The anti-LILRB1 antibody or its antigen-binding fragment provided in this disclosure can be co-administered with another drug, such as at least one selected from conventionally used immunotherapeutic agents, anticancer agents, cytotoxic agents, etc. Therefore, one embodiment provides a pharmaceutical composition for combined administration for the treatment and / or prevention of cancer, comprising (1) an anti-LILRB1 antibody or its antigen-binding fragment, and (2) at least one selected from immunotherapeutic agents, anticancer agents, cytotoxic agents, etc. Another embodiment provides a method for treating and / or preventing cancer, the method comprising administering (1) an anti-LILRB1 antibody or its antigen-binding fragment, and (2) at least one selected from immunotherapeutic agents, anticancer agents, cytotoxic agents, etc., to a subject requiring treatment and / or prevention of cancer. The immunotherapeutic agents, anticancer agents, and cytotoxic agents may include any drug conventionally used for cancer treatment and / or having cytotoxic activity, and for example, they may be at least one selected from proteins such as antibodies, nucleic acid molecules such as siRNA, and / or small molecule chemicals such as paclitaxel, docetaxel, etc., but are not limited thereto.
[0088] Another embodiment provides a polypeptide molecule comprising the heavy chain complementarity-determining region (CDR-H1, CDR-H2, CDR-H3 or a combination thereof), the light chain complementarity-determining region (CDR-L1, CDR-L2, CDR-L3 or a combination thereof), or a heavy chain variable region, a light chain variable region, or a combination thereof, of an anti-LILRB1 antibody as described above. The polypeptide molecule can be used as a precursor for antibody preparation or as a component in a protein scaffold (e.g., peptide body), bispecific antibody, or multispecific antibody having an antibody-like structure. In another embodiment, the polypeptide molecule can be used as a target (antigen) recognition domain or a secretory antibody in cell therapeutic agents such as CAR-T for targeted therapy. In another embodiment, the polypeptide molecule can be used to construct anti-LILRB1 antibody-secreting cells as a cell therapeutic agent.
[0089] Another embodiment provides a nucleic acid molecule encoding a heavy chain complementarity-determining region (CDR-H1, CDR-H2, CDR-H3 or a combination thereof), a heavy chain variable region, or a heavy chain of an anti-LILRB1 antibody.
[0090] Another embodiment provides a nucleic acid molecule encoding a light chain complementarity-determining region (CDR-L1, CDR-L2, CDR-L3 or a combination thereof), a light chain variable region, or a light chain of an anti-LILRB1 antibody.
[0091] Another embodiment provides a recombinant vector, which comprises a nucleic acid molecule encoding a heavy chain variable region or heavy chain encoding an anti-LILRB1 antibody, either separately in two separate vectors or together in one vector.
[0092] Another implementation provides a recombinant cell containing nucleic acid molecules or a recombinant vector.
[0093] The term "vector" refers to a tool used to express a target gene in a host cell, such as plasmid vectors, granular vectors, and viral vectors such as phage vectors, lentiviral vectors, adenovirus vectors, retroviral vectors, and adeno-associated virus vectors. Recombinant vectors can be constructed from or by manipulating plasmids (e.g., pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series, pUC19, etc.), phages (e.g., λgt4λB, λ-Charon, λΔz1, M13, etc.), or viral vectors (e.g., SV40, etc.), which are commonly used in the art.
[0094] In recombinant vectors, nucleic acid molecules can be operatively linked to promoters. The term "operatively linked" refers to a functional connection between a target nucleotide sequence and an expression regulatory sequence (e.g., a promoter sequence). When "operatively linked," the regulatory element can control the transcription and / or translation of the target polynucleotide.
[0095] Recombinant vectors can typically be constructed as cloning vectors or expression vectors. For recombinant expression vectors, vectors commonly available in the relevant art for expressing foreign proteins in plant, animal, or microbial cells can be used. Various methods well-known in the art can be used to construct recombinant vectors.
[0096] For use in a host, such as a prokaryotic or eukaryotic cell, a recombinant vector can be constructed accordingly. For example, when constructing a vector as an expression vector for a prokaryotic host, the vector typically includes a strong promoter for transcription (e.g., pL). λ Expression vectors for eukaryotic hosts include, but are not limited to, promoters (such as CMV promoters, trp promoters, lac promoters, tac promoters, T7 promoters, etc.), ribosome-binding sites for initiating translation, and transcription / translation termination sequences. On the other hand, expression vectors for eukaryotic hosts include, but are not limited to, origins of replication operable in eukaryotic cells, such as the f1 origin of replication, SV40 origin of replication, pMB1 origin of replication, adenovirus origin of replication, AAV origin of replication, and BBV origin of replication. Furthermore, expression vectors typically include promoters derived from mammalian cell genomes (e.g., metallothionein promoters) or promoters derived from mammalian viruses (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, HSV tk promoter, etc.), and polyadenylated sequences as transcription termination sequences.
[0097] Recombinant cells can be prepared by introducing a recombinant vector into a suitable host cell. Any host cell known in the art can be used in this disclosure, provided that it allows the recombinant vector to be continuously cloned and expressed in a stable manner. Examples of prokaryotic host cells that can be used in this disclosure include Escherichia coli species such as E. coli JM109, E. coli BL21, E. coli RR1, E. coli LE392, E. coli B, E. coli X 1776, and E. coli W3110; Bacillus species such as Bacillus subtilis and Bacillus thuringiensis; and Enterobacteriaceae strains such as Salmonella typhimurium, Serratia marcescens, and various Pseudomonas species. Eukaryotic host cells that can be used for transformation can be selected from, but are not limited to, Saccharomyces cerevisiae, insect cells, and animal cells, such as Sp2 / 0, CHO (Chinese hamster ovary) K1, CHO DG44, CHO S, CHO DXB11, CHO GS-KO, PER.C6, W138, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN, MDCK, etc.
[0098] Nucleic acid molecules or recombinant vectors carrying nucleic acid molecules can be introduced (transfected) into host cells using methods well-known in the relevant fields. For example, when the host cell is a prokaryotic cell, such transfection can be performed using CaCl2 or electroporation. For eukaryotic host cells, gene introduction can be achieved using, but is not limited to, microinjection, calcium phosphate precipitation, electroporation, liposome-mediated transfection, or particle bombardment.
[0099] To select host cells for transformation, phenotypes associated with selection markers can be utilized according to methods well-known in the art. For example, when the selection marker is a gene conferring resistance to certain antibiotics, host cells can be grown in a culture medium in the presence of antibiotics to select target transformants.
[0100] Another embodiment provides a method for preparing an anti-LILRB1 antibody or an antigen-binding fragment thereof, the method comprising expressing a nucleic acid molecule or a recombinant vector in host cells. The expression step can be performed by culturing recombinant cells containing the nucleic acid molecule (e.g., in a recombinant vector) under conditions that allow for the expression of the nucleic acid molecule. The method may further include isolating and / or purifying the antibody or a fragment thereof from the cell culture after the expression or culture step.
[0101] Beneficial effects
[0102] The anti-LILRB1 antibody or its antigen-binding fragment provided in this disclosure can inhibit the immune escape mechanism of cancer cells, thereby enabling immune cells to exhibit their anti-cancer effects and thus possessing high anti-cancer efficacy. Attached Figure Description
[0103] Figure 1 This is an electrophoresis diagram showing the SDS-PAGE gel analysis results of the purified anti-LILRB1 antibody in the examples.
[0104] Figure 2 This is a sensor image showing the SPR (surface plasmon resonance) measurement results of anti-LILRB1 antibody B3 according to one embodiment.
[0105] Figure 3 This is a sensor graph showing the SPR measurement results of anti-LILRB1 antibody E3 according to one embodiment.
[0106] Figure 4a This is a graph showing the binding ability of anti-LILRB1 antibody A10 to human natural killer cells KHYG-1 according to one embodiment; Figure 4b This is a graph showing the binding ability of anti-LILRB1 antibody E3 to human natural killer cells KHYG-1 according to one embodiment; and Figure 4c This is a graph showing the binding ability of human IgG4 isotype control antibody to human natural killer cells KHYG-1.
[0107] Figure 5 This is a graph showing the binding levels of recombinant LILRB1-Fc protein to the surface of HLA-G overexpressing cells, as measured by the iQue screener, when treated with anti-LILRB1 antibody and human IgG4 isotype control antibody according to one embodiment, respectively.
[0108] Figure 6 This is a graph showing the in vivo antitumor effects of anti-LILRB1 antibodies E3 and B3 according to one embodiment.
[0109] Figures 7a to 7d This is a flow cytometry diagram of the binding of anti-LILRB1 antibody E3.1 to cells expressing various members of the human LILR family, according to one embodiment.
[0110] Figures 8a to 8d This is a flow cytometry diagram of the binding of anti-LILRB1 antibody H11 to cells expressing various members of the human LILR family, according to one embodiment.
[0111] Figure 9This is a graph showing a comparison of the release level of granzyme B in human natural killer cells KHYG-1 when treated with anti-LILRB1 antibody E3.1 or H11 according to one embodiment with the release level of granzyme B in cells treated with a control antibody (human IgG4 isotype).
[0112] Figure 10 This is a graph showing a comparison of the perforin release levels in human natural killer cells KHYG-1 when treated with anti-LILRB1 antibody E3.1 or H11 according to one embodiment with the perforin release levels in cells treated with a control antibody (human IgG4 isotype).
[0113] Figure 11 This is a graph showing the results of a luciferase reporter assay used to evaluate the ability of anti-LILRB1 antibody E3.1 or H11 according to one embodiment to block the LILRB1 signaling pathway.
[0114] Figure 12 This is a graph showing the in vivo antitumor effects of anti-LILRB1 antibodies E3.1 and H11 according to one embodiment. Detailed Implementation
[0115] The present invention will be described in detail below through examples.
[0116] The following examples are intended to illustrate the present invention only and should not be construed as limiting the invention.
[0117] Example 1: Preparation of human antibodies against LILRB1
[0118] 1.1. Using phage display to select human antibodies against LILRB1
[0119] To select antibodies that specifically recognize human LILRB1, phage display screening was performed using a library of human scFv antibodies. Human LILRB1-His (catalog number 8989-T2) and human LILRB1-Fc (catalog number 2017-T2) (RnD systems) were used as antigens. Each antigen was conjugated with biotin using the EZ-Link sulfonyl-NHS-biotin kit (ThermoFisherScientific).
[0120] Phage display screening was performed using a total of four types of LILRB1 antigens (LILRB1-His, LILRB1-Fc, LILRB1-His-Biotin, and LILRB1-Fc-Biotin) through both solid-phase and solution-phase screening. Additional screening was performed by gradually decreasing the concentration of the antigen used, competitive elution against LILRB1 with a control antibody, negative selection of Fc when LILRB1-Fc was used as the antigen, and so on. The binding of the selected products to the antigens was confirmed by polyclonal phage ELISA.
[0121] 1.2. Screening and analysis of monoclonal soluble scFv
[0122] In Example 1.1, the gene encoding scFv that binds to the antigen was amplified by PCR to prepare an expression vector. For each selection, a certain number of transformants were transferred to 96-well plates for screening. Antibodies in the form of scFv were expressed using self-inducing medium (Studier, FW (2005) Protein Expression and Purification 41, 207-34), and their binding to the antigen was analyzed by DELFIA immunoassay (PerkinElmer). Additionally, after capturing a certain amount of each scFv antibody on the surface, the antigen was subjected to DELFIA to determine the ranking of antigen-antibody binding affinity.
[0123] 1.3. Convert the screened scFvs into IgG antibodies.
[0124] Of the clones confirmed to bind to the antigen in Example 1.2, a total of 376 clones were selected, and the DNA sequences encoding the genes of the selected scFv were analyzed by universal DNA sequencing to remove duplicate clones. Additionally, based on the ranking of antigen-antibody binding affinity determined in Example 1.2, a total of 93 clones were selected. Genes encoding the heavy chain variable region (VH) and light chain variable region (VL) were amplified from each gene encoding the selected scFv by PCR and inserted into expression vectors (pTRIOZ-hIgG4, InvivoGen; or, alternatively, any vector containing a CMV promoter or a CMV / CHOβ-actin fusion promoter (KR10-1038126B1) and genes encoding the human IgG4 heavy chain constant region and κ or λ light chain constant region) could be used, wherein the expression vectors were designed to encode human IgG4 antibodies (IgG4 Fc: SEQ ID NO: 341, κ constant region: SEQ ID NO: 342, λ constant region: SEQ ID NO: 343). The DNA sequence of the expression vector was confirmed by sequencing.
[0125] 1.4. Preparation of the selected antibody
[0126] The vector constructed in Example 1.3 was purified using the Plasmid Plus Maxi kit (Qiagen). The purified vector was used in ExpiCHO-S TM Cells or Expi293 TM Antibodies are expressed in cells.
[0127] Specifically, by adding 80 μL of ExpiFectamine TM The CHO reagent (Thermo Fisher) was used to transfect the vector constructed in Example 1.3 into ExpiCHO-S. TM Cells (Gibco) (1.5 × 10) 8 One day after transfection, 150 μL of ExpiCHO was added to the culture medium (25 mL cells / culture volume). TM Enhancer (Thermo Fisher) and 4mL ExpiCHO TM Feed (ThermoFisher) was added to the culture. On day 5, 4 mL of ExpiCHO was added. TM Feed was added to the culture. Transfected cells were cultured at 32°C and 5% CO2 for a total of 7–11 days.
[0128] Additionally, according to the manufacturer's instructions, 320 μL of ExpiFectamine was added. TM 293 reagent (Gibco) was used to transfect the vector constructed in Example 1.3 into Expi293F. TM Cells (Gibco) (3×10) 8 One day after transfection, add ExpiFectamine. TM 293Enhancer 1 (Thermo Fisher), ExpiFectamine TM Enhancer 2 (Thermo Fisher) and glucose were administered at concentrations of 0.6 mL / 100 mL culture volume, 6 mL / 100 mL culture volume, and 3.6 g / 1 liter, respectively. Transfected cells were cultured at 36.5°C and 5% CO2 for a total of 5 days.
[0129] Both types of cultured cells were centrifuged at 4000 rpm for 20 minutes at 4°C, and then filtered using a 0.22 μm top-mounted filtration system (Corning). The culture supernatant was collected and purified using AKTA Pure L (GE Healthcare). The culture supernatant was loaded into an AKTA Pure L column equipped with a Hitrap MabSelectSure 1 mL column (GE Healthcare) at a flow rate of 1 mL / min, and the column was washed with 20 column volumes (CV) of 1X PBS. Elution buffer (0.1 M sodium citrate pH 3.4 buffer) was then loaded into the column to elute the target protein. The eluent was concentrated using an Amicon Ultra Filter Device (MWCO10K, Merck), centrifuged, and buffer-exchanged with 1X PBS buffer.
[0130] Dilute the purified antibody sample with 1X PBS to a final concentration of approximately 1 mg / mL. Mix 10 μL of reducing loading buffer (3X) or non-reducing loading buffer (3X) with 20 μL of purified antibody sample, incubate at 95°C for 2 minutes, then remove and cool. Inject 10 μg of sample into each well of an SDS-PAGE gradient gel (4-20% or 4-12%) on the electrophoresis apparatus and develop on the gel. To analyze the molecular weight of the sample, use Precision Plus Protein... TM A two-color standard (BIO-RAD) was injected into a separate well. The gel was stained with Coomassie staining solution and then destained to obtain a gel image.
[0131] Among the 93 antibodies, the gel electrophoresis images of antibodies A10, B3, E3, G1, G9, and H2 are representatively shown. Figure 1 In the middle. For example Figure 1 As shown, antibodies with disulfide bonds were confirmed to have been produced.
[0132] 1.5. Analyze the binding affinity of the selected antibody.
[0133] The binding affinity of 93 antibodies selected in Example 1.3 to the antigen LILRB1 was measured using a Biacore T200 (GE Healthcare). Anti-human IgG (Fc) antibody (GE Healthcare, catalog BR-1008-39, final concentration 25 μg / mL) was flow-converted at 5 μL / min for 360 seconds and immobilized at 5000-7000 RU using an amine conjugation kit (GE Healthcare, catalog BR-1000-508) onto the S-series sensor chip CM5 (GE Healthcare, catalog BR-1005-30). Human LILRB1 antigen protein (LILRB1-His, RnD system catalog 8989-T2) was injected at 4-9 different concentrations (3.13 nM to 1600 nM) at a flow rate of 30 μL / min to determine the affinity as shown in Table 3. a and k d Value and calculate K from it D value.
[0134] Of the 93 antibodies, 20 were selected for their superior binding affinity (K). D The antibodies (values) are summarized in Table 3. Among them, the binding affinity (K) of LILRB1 is shown. D The antibody B3, with a molecular weight of approximately 99.8 nM, exhibits LILRB1 binding affinity (K). D SPR sensor maps of antibody E3 with a molecular weight of approximately 101.2 nM are shown in [the image / image]. Figure 2 and Figure 3 middle( Figure 2 SPR sensor image of B3, Figure 3 (E3 SPR sensor diagram):
[0135] Table 3
[0136] Anti-LILRB1 antibody antigen-binding affinity (K) for human LILRB1 D )
[0137]
[0138]
[0139] 1.6. Sequence analysis of the selected antibody
[0140] In Example 1.5, among the 20 antibodies analyzed for antigen-binding affinity, the CDR, light chain variable region, heavy chain variable region, amino acid sequences of the light and heavy chains, and nucleic acid sequences encoding the light and heavy chain variable regions, as defined by Kabat numbering, were analyzed using general amino acid sequencing and DNA sequencing methods, and summarized in Tables 4 to 23:
[0141] Table 4
[0142] Antibody clone E3
[0143]
[0144]
[0145] Table 5
[0146] Antibody clone B3
[0147]
[0148]
[0149] Table 6
[0150] Antibody clone A10
[0151]
[0152]
[0153] Table 7
[0154] Antibody clone G1
[0155]
[0156]
[0157] Table 8
[0158] Antibody clone G9
[0159]
[0160]
[0161] Table 9
[0162] Antibody clone H2
[0163]
[0164]
[0165] Table 10
[0166] Antibody clone H11
[0167]
[0168] Table 11
[0169] Antibody clone F12
[0170]
[0171] Table 12
[0172] Antibody clone B9
[0173]
[0174]
[0175] Table 13
[0176] Antibody clone G11
[0177]
[0178]
[0179] Table 14
[0180] Antibody clone G6
[0181]
[0182]
[0183] Table 15
[0184] Antibody clone F11
[0185]
[0186]
[0187] Table 16
[0188] Antibody clone D3
[0189]
[0190]
[0191] Table 17
[0192] Antibody clone B12
[0193]
[0194]
[0195] Table 18
[0196] Antibody clone E4
[0197]
[0198]
[0199] Table 19
[0200] Antibody clone E12
[0201]
[0202]
[0203] Table 20
[0204] Antibody clone D1
[0205]
[0206]
[0207] Table 21
[0208] Antibody clone E6
[0209]
[0210] Table 22
[0211] Antibody clone E9
[0212]
[0213] Table 23
[0214] Antibody clone A11
[0215]
[0216]
[0217] Example 2: In vitro bioactivity assay of the selected antibody
[0218] 2.1. Natural Killer Cell (NK Cell) Surface Binding Assay
[0219] To test whether the 93 antibodies selected in Example 1.4 bind to LILRB1 expressed on the surface of immune cells, a natural killer cell (NK cell) surface binding assay was performed. Human NK cells and KHYG-1 cells (JCRB) were cultured in RPMI 1640 medium (Gibco) supplemented with 10% (w / v) FBS (Gibco) and 100 U / mL interleukin-2 (Novartis). KHYG-1 cells were cultured at 5 × 10⁻⁶ cells / mL. 4A cell / well ratio of 10 cells / well was added to a U-bottom 96-well tissue culture plate (BDFalcon). Each selected antibody was added to the wells to a final concentration of 50 μg / mL per well and incubated at 4°C for 1 hour.
[0220] To determine the LILRB1-specific binding level of the selected antibody, the human IgG4 isotype control antibody (Biolegend) was treated in the same manner. After washing with FACS buffer, cells were treated with anti-human Fc-biotin antibody (Life Technologies) and incubated at 4°C for 1 hour. After washing with FACS buffer, cells were treated with streptavidin PE (BD Pharmigen) and incubated at 4°C for 30 minutes. After washing with FACS buffer, the cells were resuspended and analyzed using the iQue screener (Sartorius).
[0221] In the obtained results, representative comparisons were made between the results for antibodies A10, E3, E4, F12, G1, G9, G11, H2, and H11 and the results for human IgG4 isotype (control), as shown in Table 24. Flow cytometry plots of A10, E3, and human IgG4 isotype (control) are shown in Table 24. Figure 4a (A10) Figure 4b (E3) and Figure 4c (Isotype IgG4):
[0222] Table 24
[0223] Average fluorescence intensity % of group 2 Human IgG4 isotype control 142917.2 2.95 A10 222660.2 28.68 E3 268702.2 40.22 E4 272295.5 43.25 F12 262012.7 38.02 G1 321051.7 56.23 G9 263079.3 41.32 G11 262771.9 40.11 H2 238570.9 29.00 H11 244818.2 32.59
[0224] As shown in Table 24 and Figures 4a-4c As shown, the tested antibody exhibited a higher level of binding to human NK cells (surface) compared to the human IgG4 isotype control antibody.
[0225] 2.2. Analysis of the inhibitory effect of the selected antibody on the binding of LILRB1 to HLA-G.
[0226] To test whether the antibody selected in Example 1.5 inhibits the binding of LILRB1 to its ligand HLA-G, the degree of blocking effect of the selected antibody was analyzed.
[0227] For this purpose, JEG-3 cells (ATCC catalog number HTB-36) exhibiting high HLA-G expression levels were used. JEG-3 cells were cultured in MEM medium (Gibco) supplemented with 10% (v / v) FBS (Gibco) and 1% (v / v) penicillin-streptomycin (Gibco). JEG-3 cells were cultured at 5 × 10⁻⁶ cells / year. 4Cells per well were added to a U-bottom 96-well tissue culture plate (BD Falcon). The plates were washed with 1X PBS buffer. Each antibody selected in Example 1.5 (A10, E3, F12, G1, G9, H2, and H11) and LILRB1-Fc (RnD systems) were mixed in FACS buffer (1X PBS + 1% BSA + 1mM EDTA) to a final concentration of 10 μg / mL and 5 μg / mL, respectively. Cells were treated with 100 μL of the mixture per well and incubated on ice for 2 hours. Anti-LILRB1 antibody (clone HP-F1, Abcam) as a positive control and anti-lysozyme IgG4 antibody (clone D1.3) as a negative control were treated in the same manner. After washing twice with FACS buffer, cells were treated with PE-anti-huIgG-Fc antibody (Biolegend, 10 μg / mL) and incubated on ice for one hour. After washing twice with FACS buffer, the cells were resuspended in 100 μL of the same buffer and analyzed using the iQue filter (Sartorius).
[0228] The results are shown in Figure 5 In the middle. For example Figure 5 As shown, all tested antibodies A10, E3, F12, G1, G9, H2 and H11 effectively inhibited the binding of LILRB1-Fc to HLA-G overexpressing cell lines.
[0229] 2.3. Determination of NK cell-induced cancer cell lysis
[0230] To test whether the selected antibody increased the degree of cancer cell lysis induced by NK cells, the cell death rate of HLA-G overexpressing HEK293 cells induced by NK cell KHYG-1 was analyzed. KHYG-1 cells (JCRB) were cultured at 2 × 10⁻⁶ cells / year. 4 Cells / well (4×10) 4 Cells were added to a 96-well tissue culture plate (BD Falcon) at a concentration of 50 μL (cells / mL). Cells were treated with each antibody (Table 25) to a final concentration of 20 μg / mL per well and incubated at 37°C for one hour.
[0231] As a negative control, the human IgG4 isotype control antibody (Biolegend) was treated in the same manner.
[0232] According to the manufacturer's protocol, HLA-G overexpressing HEK293 cells (prepared by transducing HEK293 cells with a lentivirus designed for HLA-G expression, from the American Typo Culture Collection) were stained with IncuCyte CytoLight Rapid Red reagent (Sartorius). One hour later, the HLA-G overexpressing HEK293 cells were stained at 1×10⁻⁶. 4 Cells / well (2×10) 4 A concentration of cells / mL (total volume 50 μL) was added to the plate. The plate was placed in an IncuCyte S3 (Sartorius) incubator equipped with an incubator at 37°C and 5% CO2 for 72 hours and imaged. The confluence of red regions indicating the density of HLA-G overexpressing HEK293 cells was measured, and cell viability was calculated. The obtained cell viability is shown in Table 25 (where cell viability is shown as a relative value to the control antibody (cell viability = 1 for IgG4 isotype-treated wells):
[0233]
[0234] Table 25
[0235] Antibody Relative cell viability (IgG4 isotype = 1) Human IgG4 isotype control 1.00 A10 0.70 B9 0.81 D3 0.83 E1 0.82 E3 0.64 F12 0.81 G1 0.64 G6 0.78 G9 0.77 G11 0.82 H2 0.78 H11 0.60
[0236] As shown in Table 25, compared with human IgG4 isotype control antibodies, all tested antibodies, including A10, B9, D3, E1, E3, F12, G1, G6, G9, G11, H2 and H11, increased cell death in HLA-G overexpressing HEK293 cells induced by KHYG-1.
[0237] Example 3: In vivo bioactivity assay of the selected antibody
[0238] Of the antibodies selected in Example 1.5, the in vivo anticancer efficacy of two antibodies (E3 and B3) was tested. For this purpose, it was tested whether administration of the two antibodies would reduce tumor size, wherein the tumors were generated by transplanting human colorectal cancer cells (Bioware Brite Cell Line HCT116 Red-Fluc colorectal cancer cells (PerkinElmer)) and THP-1-derived macrophages into mice. As a negative control, human colon cancer xenograft mice prepared as described above were treated with a human IgG1 isotype control antibody (BioXcell, catalog number BP0297). The procedure is described in detail below:
[0239] Preparation of THP-1-derived macrophages
[0240] The THP-1-derived macrophages used above were prepared by differentiating THP-1 cells (ATCC) with 150 nM phorbol 12-myristate 13-acetate (PMA, Sigma), 20 ng / mL interferon-γ (Peprotech), and 10 pg / mL lipopolysaccharide (LPS, Sigma).
[0241] Measuring anticancer efficacy in mouse models
[0242] Five-week-old female CIEA NOG mice (Central Institute for Experimental Animals, Japan) were subcutaneously injected with 3 × 10⁻⁶ mol / L mol / L. 6 HCT116 Red-Fluc colorectal cancer cells, 3×10⁶ cells 6 A mixture of THP-1-derived macrophages and one of two test antibodies (E3 or B3 antibody; 20 μg per mouse) was administered to the mouse model twice weekly via intraperitoneal injection, starting on day 4 post-tumor transplantation. The size of the transplanted tumor (mm) was then measured. 3 ) and displayed in Figure 6 In the middle. For example Figure 6 As shown, all tested antibodies, especially antibody E3, exhibited statistically significant inhibitory effects on tumor growth in mouse models transplanted with HCT116 colon cancer cells and THP-1-derived macrophages.
[0243] Example 4: Preparation of anti-LILRB1 antibody (E3.1)
[0244] The nucleic acid sequence encoding the full-length heavy chain (SEQ ID NO: 302) of antibody E3 (which was confirmed to have a particularly significant effect in Example 3) was amplified by PCR. The nucleic acid sequence encoding the Ser1 to Leu110 regions of the light chain variable region (VL) (SEQ ID NO: 221) of antibody E3 was amplified by PCR and ligated to the nucleic acid sequence encoding the λ constant region (λCL.1, SEQ ID NO: 344) to amplify the nucleic acid sequence encoding the λ light chain by PCR. The amplified sequence was inserted into an expression vector (pTRIOZ-hIgG4, InvivoGen; or, alternatively, a vector containing a CMV promoter or a CMV / CHOβ-actin fusion promoter (KR10-1038126B1) and genes encoding the human IgG4 heavy chain constant region and the λ light chain constant region, wherein the expression vector was designed to encode a human IgG4 antibody. The DNA sequence of the expression vector was confirmed by sequencing.
[0245] The antibody (E3.1) was prepared using the constructed expression vector as described in Example 1.4, and the antibody sequence was analyzed as described in Example 1.6 and summarized in Table 26.
[0246] Table 26
[0247] Antibody clone E3.1
[0248]
[0249]
[0250] Example 5: Generation of human LILR overexpressing cell lines
[0251] Nucleic acid sequences encoding full-length human LILR family proteins (Table 27) were amplified by PCR, and each amplified sequence was inserted into an expression vector (pTRIOZ-hIgG4, InvivoGen; or, alternatively, a vector containing a CMV promoter or a CMV / CHO β-actin fusion promoter (KR10-1038126B1) and genes encoding the human IgG4 heavy chain constant region and λ light chain constant region). The DNA sequences of the expression vectors were confirmed by sequencing. The constructed vectors were transfected into CHO cells to generate 11 stable cell lines overexpressing each LILR protein on their surface.
[0252] Table 27
[0253]
[0254]
[0255]
[0256]
[0257] Example 6: Determining the binding of the selected antibody to the surface of LILRB1-overexpressing cells. 50
[0258] To determine the EC5 binding of the antibodies prepared in Examples 1 and 4 to the human LILRB1 overexpressing cell line. 50 Cell surface binding was measured using the values. The values represent the prepared antibodies; EC50 values of the E3.1 and H11 antibodies were measured. 50 Value. CHO cells overexpressing LILRB1 on their surface, prepared in Example 5, were used at 1×10⁻⁶. 5Cells / well were added to 96-well U-bottom tissue culture plates (BD Falcon). Serial three-fold dilutions of E3.1 and H11 antibodies were prepared, starting at final concentrations of 600 μg / mL and 27 μg / mL, respectively. Cells were treated with each antibody dilution and incubated at 4°C for 60 min. After washing with FACS buffer, cells were treated with anti-human Fc-biotin antibody (Invitrogen) and incubated at 4°C for 30 min. After washing with FACS buffer, cells were treated with PE-labeled streptavidin (BD Pharmigen) and incubated at 4°C for 30 min. After washing with FACS buffer, cells were resuspended and analyzed using the iQue screener (Sartorius). EC was calculated using a nonlinear regression formula in GraphPad Prism software. 50 The values are given, and the results are shown in Table 28:
[0259] Table 28
[0260] E3.1 H11 <![CDATA[EC 50 (nM)]]> 7.154 0.376
[0261] Example 7: Evaluation of the cross-reactivity of the selected antibody to human LILR family overexpressing cell lines
[0262] To confirm whether the selected antibody binds to human LILR family proteins other than LILRB1, a cell surface binding assay was performed. CHO cells (prepared in Example 5) expressing one of the various LILR family proteins on their surface were subjected to a 1×10⁻⁶ assay. 5 Cells per well were added to 96-well U-bottom tissue culture plates (BD Falcon). Each well was treated with the selected antibody at a final concentration of 20 μg / mL and incubated at 4°C for 60 min. After washing with FACS buffer, cells were treated with anti-human Fc-biotin antibody (Invitrogen) and incubated at 4°C for 30 min. After washing with FACS buffer, cells were treated with PE or FITC-labeled streptavidin (BD Pharmigen) and incubated at 4°C for 30 min. After washing with FACS buffer, cells were resuspended and analyzed using the iQue screen (Sartorius). Cells treated with each LILR protein-specific antibody (Table 27) served as positive controls, and cells treated with human IgG4 isotype control antibody (Biolegend) served as negative controls.
[0263] The results obtained for antibody E3.1 are shown in Figures 7a to 7d (E3.1: red; LILR-specific antibody: blue; isotype (hIgG4) control: gray), and the results obtained for antibody H11 are shown in Figures 8a to 8d(H11: red; LILR-specific antibody: blue; isotype (hIgG4) control: gray). For example... Figures 7a to 7d and Figures 8a to 8d As shown, the E3.1 and H11 antibodies do not bind at all or almost not bind to LILRs other than LILRB1. These results indicate that the antibodies provided by the examples have the ability to specifically bind to LILRB1.
[0264] Example 8: Measurement of granzyme B and perforin release by enzyme-linked immunosorbent assay (ELISPOT)
[0265] To confirm whether E3.1 and H11 antibodies increased cytotoxicity levels in NK cells, an enzyme-linked immunosorbent assay (ELISPOT) was performed. Cytotoxicity levels were determined by the release of cytotoxic granules, granzyme B, and perforin from NK cells.
[0266] 5×10 3 The KHYG-1 cell line (JCRB) expressing LILRB1 and 5 × 10 3 HLA-G overexpressing K562 cells (prepared by transducing K562 cells with a lentivirus designed for HLA-G expression (USC Type Culture Collection)) were co-cultured in 96-well U-bottom tissue culture plates. Each antibody (E3.1, H11, or human IgG4 isotype control antibody) was added to each well at a final concentration of 50 μg / mL, and the plates were incubated at 37°C for 30 minutes. The co-cultured cells were then transferred to 96-well Immunospot (catalog HGZBPFN-2M) 96-well plates for ELISPOT (PVDF membranes), which were coated with anti-perforin and anti-granzyme B antibodies respectively, and further incubated at 37°C for 8 hours. The PVDF membranes were washed with washing solution (0.05% Tween 20 in PBS) and then treated with anti-granzyme B-HRP and anti-perforin-biotin antibodies. The assay process was then performed according to the manufacturer's protocol. The PVDF membrane was dried at room temperature for 24 hours, and the number of spots of granzyme B and perforin was counted using an ELISPOT analyzer (Immunospot).
[0267] The results are shown in the following figures. Figure 9 (Granzyme b; Gzmb) and Figure 10 In (perforin; Prf) (the Y-axis represents the total number of spots). For example... Figure 9 and Figure 10As shown, compared with the human IgG4 isotype control antibody treatment group, the release levels of granzyme B and perforin were significantly increased in the E3.1 or H11 antibody treatment groups. Unpaired t-tests were performed, and all experiments were conducted three times under identical conditions to ensure experimental reliability. Results are presented as mean values.
[0268] Example 9: Preparation of chimeric GHI / 75 antibody
[0269] To understand whether the antibodies provided in the examples exhibit higher efficacy compared to previously existing antibodies, a chimeric GHI / 75 antibody was prepared comprising the variable region of a GHI / 75 antibody (Biolegend, catalog number 333721, which is a mouse-derived anti-human LILRB1 antibody) and the constant region of a human antibody.
[0270] More specifically, the amino acid sequence of the GHI / 75 antibody was analyzed by peptide localization, and a vector was prepared in which the nucleic acid sequence corresponding to the variable region (VH and VL domains) of the human IgG4 antibody was replaced with the nucleic acid sequence corresponding to the variable region (VH and VL domains) of the mouse GHI / 75 antibody. In the vector, the region corresponding to the upper hinge of human IgG4 was replaced with the nucleic acid sequence corresponding to the amino acid sequence of the upper hinge of human IgG1 (EPKSCDKTHT; SEQ ID NO:359). The vector was expressed as described in Example 1.4, and the obtained antibody was purified and used as the comparative antibody in the following examples.
[0271] Example 10: Measurement of the inhibitory effect of the selected antibody on LILRB1 signaling using IL-2 promoter luciferase assay.
[0272] To confirm whether the antibodies prepared in Examples 1 and 4 inhibited LILRB1 signaling, a luciferase reporter assay was performed. Representative E3.1 and H11 antibodies from the antibodies prepared in Examples 1 and 4 were assayed and compared with the chimeric GHI / 75 antibody prepared in Example 9. Jurkat cells expressing LILRB1 and interleukin-2 (IL-2) promoter luciferase (prepared by inserting the IL-2 promoter luciferase vector (Promega) into the Jurkat cell line (USC Type Culture Collection), followed by transduction with a lentivirus constructed for LILRB1 expression) and HLA-G overexpressing K562 cells were used. 96-well plates were coated with anti-CD3 antibody (Biolegend) after overnight incubation at 4°C. The following day, Jurkat cells expressing LILRB1 and IL-2 promoter luciferase were cultured at 1 × 10⁻⁶ cells per well. 5Cells / well were added to U-bottom 96-well plates, and the plates were treated with each antibody (E3.1, H11, chimeric GHI / 75, or human IgG4 isotype (control)) to a final concentration of 20 μg / mL, and incubated at 37°C for one hour. HLA-G overexpressing K562 cells (1 × 10⁻⁶ cells / well) were then added. 5 Add cells / well to the plate and incubate at 37°C for 30 minutes. Transfer the resulting suspension to a plate coated with anti-CD3 antibody and add anti-CD28 antibody (Biolegend) to a final concentration of 10 μg / mL. Incubate the plate at 37°C for 6 hours. Steady- The solution (Promega) was added to each well, and the luminescence intensity was recorded using a photometer (Envision, PerkinElmer).
[0273] The results are shown in Figure 11 In the middle. For example Figure 11 As shown, compared with the human IgG4 isotype control antibody and the chimeric GHI / 75 control antibody, the E3.1 and H11 antibodies provided in the examples exhibited significantly increased LILRB1 signaling inhibition activity.
[0274] Example 11: Analysis of the anticancer effects of selected antibodies in a mouse model
[0275] To analyze the anticancer effect of the selected antibody, referring to Example 3, 3 × 10⁻⁶ antibodies were subcutaneously injected into 5-week-old female CIEA NOG mice (NOG immunodeficient mice; Central Institute for Experimental Animals, Japan). 6 HCT116 Red-Fluc colorectal cancer cells, 3×10⁶ cells 6 A mixture of THP-1-derived macrophages and antibody (20 μg / mouse) was used. The antibody used was either E3.1 or H11, and human IgG4 isotype was used as a control antibody for comparison. Starting on day 4 after tumor cell transplantation, the antibody was administered to the mouse model twice weekly via intraperitoneal injection at a dose of 5 mg / kg, and tumor volume was measured and displayed. Figure 12 In the middle. For example Figure 12 As shown, compared with the control antibody, the E3.1 and H11 antibodies exhibited significant inhibitory effects on tumor growth in mouse models transplanted with HCT116 colon cancer cells and THP-1-derived macrophages. <110> LG CHEM, LTD. <120> Anti-LILRB1 antibodies and their uses <130> OPP20204082KR <150> 10-2019-0173414 <151> 2019-12-23 <150> 10-2020-0061907 <151> 2020-05-22 <160> 359 <170> koPatentIn 3.0 <210> 1 <211> 11 <212> PRT <213> Artificial sequence <220> <223> CDR-L1 (Kabat) for E3 or E3.1 <400> 1 Gln Gly Asp Ser Leu Arg Asn Phe Tyr Ala Ser 1 5 10 <210> 2 <211> 7 <212> PRT <213> Artificial sequence <220> <223> CDR-L2 (Kabat) for E3 or E3.1 <400> 2 Gly Lys Asn Asn Arg Pro Ser 1 5 <210> 3 <211> 13 <212> PRT <213> Artificial sequence <220> <223> CDR-L3 (Kabat) for E3 or E3.1 <400> 3 Asn Ser Arg Asp Ser Ser Gly Ser His Leu Thr Gly Val 1 5 10 <210> 4 <211> 5 <212> PRT <213> Artificial sequence <220> <223> CDR-H1 (Kabat) of E3 or E3.1 <400> 4 Ser Tyr Ala Met Ser 1 5 <210> 5 <211> 17 <212> PRT <213> Artificial sequence <220> <223> CDR-H2 (Kabat) of E3 or E3.1 <400> 5 Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 6 <211> 15 <212> PRT <213> Artificial sequence <220> <223> CDR-H3 (Kabat) of E3 or E3.1 <400> 6 Asp Thr Tyr Tyr Tyr Gly Ser Gly Arg Ser Asn Ala Phe Asp Ile 1 5 10 15 <210> 7 <211> 11 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-L1 (Kabat) <400> 7 Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 8 <211> 7 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-L2 (Kabat) <400> 8 Asp Ala Ser Asn Leu Glu Thr 1 5 <210> 9 <211> 7 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-L3 (Kabat) <400> 9 Gln Gln Tyr Asp Asn Leu Pro 1 5 <210> 10 <211> 5 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-H1 (Kabat) <400> 10 Asp Tyr Ala Met His 1 5 <210> 11 <211> 17 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-H2 (Kabat) <400> 11 Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 12 <211> 13 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-H3 (Kabat) <400> 12 Val Gly Asp Ser Ser Gly Trp Ser Asp Ala Phe Asp Ile 1 5 10 <210> 13 <211> 11 <212> PRT <213> Artificial sequence <220> <223> A10's CDR-L1 (Kabat) <400> 13 Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala 1 5 10 <210> 14 <211> 7 <212> PRT <213> Artificial sequence <220> <223> A10's CDR-L2 (Kabat) <400> 14 Gly Ala Ser Thr Arg Ala Thr 1 5 <210> 15 <211> 11 <212> PRT <213> Artificial sequence <220> <223> A10's CDR-L3 (Kabat) <400> 15 Gln Gln Tyr Gly Ser Ser Pro Arg Met Tyr Thr 1 5 10 <210> 16 <211> 5 <212> PRT <213> Artificial sequence <220> <223> A10 CDR-H1 (Kabat) <400> 16 Ser Tyr Ala Ile Ser 1 5 <210> 17 <211> 17 <212> PRT <213> Artificial sequence <220> <223> A10's CDR-H2 (Kabat) <400> 17 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 18 <211> 12 <212> PRT <213> Artificial sequence <220> <223> A10 CDR-H3 (Kabat) <400> 18 Gly Gly Leu Gly Glu Leu Asp Asn Trp Phe Asp Pro 1 5 10 <210> 19 <211> 11 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-L1 (Kabat) <400> 19 Ser Gly Tyr Lys Leu Gly Asp Arg Tyr Val Ser 1 5 10 <210> 20 <211> 7 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-L2 (Kabat) <400> 20 Lys Asp Ser Gln Arg Pro Ser 1 5 <210> twenty one <211> 9 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-L3 (Kabat) <400> twenty one Gln Ala Trp Asp Ser Gly Thr Gly Val 1 5 <210> twenty two <211> 5 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-H1 (Kabat) <400> twenty two Ser Tyr Gly Ile Ser 1 5 <210> twenty three <211> 17 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-H2 (Kabat) <400> twenty three Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Glu Leu Gln 1 5 10 15 Gly <210> twenty four <211> 9 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-H3 (Kabat) <400> twenty four Val Gly Val Ala Gly Lys Leu Asp Tyr 1 5 <210> 25 <211> 14 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-L1 (Kabat) <400> 25 Thr Gly Ser Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 26 <211> 7 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-L2 (Kabat) <400> 26 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 27 <211> 12 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-L3 (Kabat) <400> 27 Ser Ser Tyr Thr Gly Ser Ser Thr Leu Asp Val Leu 1 5 10 <210> 28 <211> 5 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-H1 (Kabat) <400> 28 Ser Tyr Trp Ile Gly 1 5 <210> 29 <211> 17 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-H2 (Kabat) <400> 29 Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln 1 5 10 15 Gly <210> 30 <211> 11 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-H3 (Kabat) <400> 30 Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val 1 5 10 <210> 31 <211> 11 <212> PRT <213> Artificial sequence <220> <223> H2's CDR-L1 (Kabat) <400> 31 Gln Gly Asp Ser Leu Arg Asn Tyr Tyr Ala Ser 1 5 10 <210> 32 <211> 7 <212> PRT <213> Artificial sequence <220> <223> H2's CDR-L2 (Kabat) <400> 32 Gly Asn Asn Lys Arg Pro Ser 1 5 <210> 33 <211> 11 <212> PRT <213> Artificial sequence <220> <223> H2's CDR-L3 (Kabat) <400> 33 Asn Ser Leu Asp Ser Thr Tyr Asn His Pro Ile 1 5 10 <210> 34 <211> 5 <212> PRT <213> Artificial sequence <220> <223> CDR-H1 (Kabat) of H2 <400> 34 Ser Tyr Asp Ile His 1 5 <210> 35 <211> 17 <212> PRT <213> Artificial sequence <220> <223> CDR-H2 (Kabat) of H2 <400> 35 Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln 1 5 10 15 Gly <210> 36 <211> 8 <212> PRT <213> Artificial sequence <220> <223> CDR-H3 (Kabat) of H2 <400> 36 Asp Gly Gly Asp Ala Phe Asp Ile 1 5 <210> 37 <211> 11 <212> PRT <213> Artificial sequence <220> <223> H11's CDR-L1 (Kabat) <400> 37 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser 1 5 10 <210> 38 <211> 7 <212> PRT <213> Artificial sequence <220> <223> H11's CDR-L2 (Kabat) <400> 38 Gly Arg Asn Asn Arg Pro Ser 1 5 <210> 39 <211> 11 <212> PRT <213> Artificial sequence <220> <223> H11's CDR-L3 (Kabat) <400> 39 Lys Ser Arg Asp Ser Ser Gly Asn His Tyr Val 1 5 10 <210> 40 <211> 5 <212> PRT <213> Artificial sequence <220> <223> H11 CDR-H1 (Kabat) <400> 40 Ser Tyr Tyr Met His 1 5 <210> 41 <211> 17 <212> PRT <213> Artificial sequence <220> <223> H11 CDR-H2 (Kabat) <400> 41 Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 42 <211> 8 <212> PRT <213> Artificial sequence <220> <223> H11 CDR-H3 (Kabat) <400> 42 Asp Ala Gly Ser Ser Ser Asp Tyr 1 5 <210> 43 <211> 14 <212> PRT <213> Artificial sequence <220> <223> F12's CDR-L1 (Kabat) <400> 43 Ala Gly Thr Ser Ser Asp Ile Gly Asp Tyr Asp Tyr Val Ser 1 5 10 <210> 44 <211> 7 <212> PRT <213> Artificial sequence <220> <223> F12's CDR-L2 (Kabat) <400> 44 Asp Val Ser Arg Arg Pro Ser 1 5 <210> 45 <211> 10 <212> PRT <213> Artificial sequence <220> <223> F12's CDR-L3 (Kabat) <400> 45 Ala Ser Tyr Thr Ser Ser Ser Ser Val Val Val 1 5 10 <210> 46 <211> 5 <212> PRT <213> Artificial sequence <220> <223> F12 CDR-H1 (Kabat) <400> 46 Ser Tyr Trp Ile Gly 1 5 <210> 47 <211> 17 <212> PRT <213> Artificial sequence <220> <223> F12 CDR-H2 (Kabat) <400> 47 Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln 1 5 10 15 Gly <210> 48 <211> 11 <212> PRT <213> Artificial sequence <220> <223> F12 CDR-H3 (Kabat) <400> 48 Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val 1 5 10 <210> 49 <211> 11 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-L1 (Kabat) <400> 49 Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn 1 5 10 <210> 50 <211> 7 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-L2 (Kabat) <400> 50 Gly Ala Ser Ser Ser Leu Gln Ser 1 5 <210> 51 <211> 9 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-L3 (Kabat) <400> 51 Gln Gln Ala Tyr Gly Phe Pro Leu Thr 1 5 <210> 52 <211> 5 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-H1 (Kabat) <400> 52 Ser Tyr Ala Ile Ser 1 5 <210> 53 <211> 17 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-H2 (Kabat) <400> 53 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 54 <211> 16 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-H3 (Kabat) <400> 54 Gly Glu Ile Ala Val Ala Gln Asn Trp Asp Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 55 <211> 14 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-L1 (Kabat) <400> 55 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 56 <211> 7 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-L2 (Kabat) <400> 56 Asp Val Ser Lys Arg Pro Ser 1 5 <210> 57 <211> 11 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-L3 (Kabat) <400> 57 Ser Ser Tyr Ser Ser Ser Ser Ser Thr Leu Val Val 1 5 10 <210> 58 <211> 5 <212> PRT <213> Artificial sequence <220> <223> G11 CDR-H1 (Kabat) <400> 58 Ser Tyr Trp Ile Gly 1 5 <210> 59 <211> 17 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-H2 (Kabat) <400> 59 Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln 1 5 10 15 Gly <210> 60 <211> 11 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-H3 (Kabat) <400> 60 Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val 1 5 10 <210> 61 <211> 11 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-L1 (Kabat) <400> 61 Gln Gly Asp Ser Leu Arg Arg Tyr Tyr Ala Thr 1 5 10 <210> 62 <211> 7 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-L2 (Kabat) <400> 62 Gly Gln Asn Tyr Arg Pro Ser 1 5 <210> 63 <211> 11 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-L3 (Kabat) <400> 63 Asn Ser Arg Asp Ser Ser Gly Asn His Val Val 1 5 10 <210> 64 <211> 5 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-H1 (Kabat) <400> 64 Ser Tyr Tyr Met His 1 5 <210> 65 <211> 17 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-H2 (Kabat) <400> 65 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 66 <211> 10 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-H3 (Kabat) <400> 66 Gly Trp Gly Tyr Ser Ser Ser Phe Asp Tyr 1 5 10 <210> 67 <211> 13 <212> PRT <213> Artificial sequence <220> <223> F11's CDR-L1 (Kabat) <400> 67 Ser Gly Ser Ser Ser Ser Asn Ile Gly Thr Asn Thr Val Asn 1 5 10 <210> 68 <211> 7 <212> PRT <213> Artificial sequence <220> <223> F11's CDR-L2 (Kabat) <400> 68 Ser Asn Asp Gln Arg Pro Ser 1 5 <210> 69 <211> 11 <212> PRT <213> Artificial sequence <220> <223> F11's CDR-L3 (Kabat) <400> 69 Glu Thr Trp Asp Asp Ser Leu Lys Gly Pro Val 1 5 10 <210> 70 <211> 5 <212> PRT <213> Artificial sequence <220> <223> F11 CDR-H1 (Kabat) <400> 70 Ser Tyr Ala Met Ser 1 5 <210> 71 <211> 17 <212> PRT <213> Artificial sequence <220> <223> F11 CDR-H2 (Kabat) <400> 71 Thr Ile Ser Gly Ser Gly Asp Ser Thr Tyr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 72 <211> 10 <212> PRT <213> Artificial sequence <220> <223> F11 CDR-H3 (Kabat) <400> 72 Glu Trp Glu Leu Gly Asp Ala Phe Asp Ile 1 5 10 <210> 73 <211> 11 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-L1 (Kabat) <400> 73 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 74 <211> 7 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-L2 (Kabat) <400> 74 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 75 <211> 9 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-L3 (Kabat) <400> 75 Gln Gln Ser Tyr Ser Thr Arg Trp Thr 1 5 <210> 76 <211> 5 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-H1 (Kabat) <400> 76 Ser Tyr Ala Met Ser 1 5 <210> 77 <211> 17 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-H2 (Kabat) <400> 77 Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 78 <211> 13 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-H3 (Kabat) <400> 78 Asp Arg Gly Ser Tyr Gly Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 79 <211> 11 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-L1 (Kabat) <400> 79 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 80 <211> 7 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-L2 (Kabat) <400> 80 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 81 <211> 9 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-L3 (Kabat) <400> 81 Gln Gln Ser Tyr Ser Thr Leu Arg Thr 1 5 <210> 82 <211> 5 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-H1 (Kabat) <400> 82 Gly Tyr Tyr Met His 1 5 <210> 83 <211> 17 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-H2 (Kabat) <400> 83 Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 84 <211> 13 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-H3 (Kabat) <400> 84 Ala Gly Ala Ser Ile Val Gly Ala Thr Ala Leu Asp Tyr 1 5 10 <210> 85 <211> 13 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-L1 (Kabat) <400> 85 Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln 1 5 10 <210> 86 <211> 7 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-L2 (Kabat) <400> 86 Glu Asp Asn Gln Arg Pro Ser 1 5 <210> 87 <211> 11 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-L3 (Kabat) <400> 87 Gln Ser Tyr Asp Thr Gly Asn Arg Asn Tyr Val 1 5 10 <210> 88 <211> 5 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-H1 (Kabat) <400> 88 Ser Tyr Thr Ile Ser 1 5 <210> 89 <211> 17 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-H2 (Kabat) <400> 89 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 90 <211> 12 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-H3 (Kabat) <400> 90 Gly Pro Ser Leu Asn Tyr Ala Gly Tyr Phe Asp Asn 1 5 10 <210> 91 <211> 11 <212> PRT <213> Artificial sequence <220> <223> E12's CDR-L1 (Kabat) <400> 91 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser 1 5 10 <210> 92 <211> 7 <212> PRT <213> Artificial sequence <220> <223> E12's CDR-L2 (Kabat) <400> 92 Gly Lys Glu Lys Arg Pro Ser 1 5 <210> 93 <211> 11 <212> PRT <213> Artificial sequence <220> <223> E12's CDR-L3 (Kabat) <400> 93 Asn Ser Arg Gly Ser Thr Thr Asp Tyr Met Val 1 5 10 <210> 94 <211> 5 <212> PRT <213> Artificial sequence <220> <223> E12 CDR-H1 (Kabat) <400> 94 Ser Tyr Ala Met His 1 5 <210> 95 <211> 17 <212> PRT <213> Artificial sequence <220> <223> E12 CDR-H2 (Kabat) <400> 95 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 96 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E12 CDR-H3 (Kabat) <400> 96 Glu Arg Gly Ser Gly Met Asp Val 1 5 <210> 97 <211> 11 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-L1 (Kabat) <400> 97 Lys Ala Ser Gln Asp Ile Asp Asp Asp Met Asn 1 5 10 <210> 98 <211> 7 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-L2 (Kabat) <400> 98 Glu Ala Ser Thr Leu Val Pro 1 5 <210> 99 <211> 9 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-L3 (Kabat) <400> 99 Leu Gln His Asp Lys Phe Pro Tyr Thr 1 5 <210> 100 <211> 5 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-H1 (Kabat) <400> 100 Ser Tyr Gly Ile Ser 1 5 <210> 101 <211> 17 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-H2 (Kabat) <400> 101 Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 102 <211> 8 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-H3 (Kabat) <400> 102 Arg Gly Val Asp Glu Gly Asp Tyr 1 5 <210> 103 <211> 13 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-L1 (Kabat) <400> 103 Thr Gly Ser Ser Gly Asn Ile Ala Ser Asn Tyr Val Gln 1 5 10 <210> 104 <211> 7 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-L2 (Kabat) <400> 104 Arg Asp Asp Gln Arg Pro Ser 1 5 <210> 105 <211> 9 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-L3 (Kabat) <400> 105 Gln Ser Tyr Asp Ser Ser Ser Trp Val 1 5 <210> 106 <211> 5 <212> PRT <213> Artificial sequence <220> <223> E6 CDR-H1 (Kabat) <400> 106 Thr Tyr Asp Ile Thr 1 5 <210> 107 <211> 17 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-H2 (Kabat) <400> 107 Trp Met Asn Pro Asn Ser Gly Asn Ser Arg Ser Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 108 <211> 15 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-H3 (Kabat) <400> 108 Gly Asp Tyr Ser Gly Val Val Leu Thr Ala Thr Ala Leu Asp Tyr 1 5 10 15 <210> 109 <211> 13 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-L1 (Kabat) <400> 109 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Tyr 1 5 10 <210> 110 <211> 7 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-L2 (Kabat) <400> 110 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 111 <211> 11 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-L3 (Kabat) <400> 111 Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 112 <211> 5 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-H1 (Kabat) <400> 112 Ser Tyr Gly Met His 1 5 <210> 113 <211> 17 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-H2 (Kabat) <400> 113 Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 114 <211> 14 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-H3 (Kabat) <400> 114 Glu Asp Arg Ile Ala Ala Ala Gly Met Arg Glu Leu Asp Tyr 1 5 10 <210> 115 <211> 16 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-L1 (Kabat) <400> 115 Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp 1 5 10 15 <210> 116 <211> 7 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-L2 (Kabat) <400> 116 Leu Gly Ser Asn Arg Ala Ser 1 5 <210> 117 <211> 10 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-L3 (Kabat) <400> 117 Met Gln Gly Thr His Trp Pro Pro Tyr Thr 1 5 10 <210> 118 <211> 5 <212> PRT <213> Artificial sequence <220> <223> A11 CDR-H1 (Kabat) <400> 118 Ser Tyr Ala Met Thr 1 5 <210> 119 <211> 17 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-H2 (Kabat) <400> 119 Gly Ile Ser Ser Asp Gly Thr Thr Thr Thr Tyr Ala Asp Ser Val Arg 1 5 10 15 Gly <210> 120 <211> 11 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-H3 (Kabat) <400> 120 Asp Gln Leu Leu Gly Trp Asp Ala Leu Asn Val 1 5 10 <210> 121 <211> 6 <212> PRT <213> Artificial sequence <220> <223> CDR-L1 (IGMT) for E3 or E3.1 <400> 121 Ser Leu Arg Asn Phe Tyr 1 5 <210> 122 <211> 3 <212> PRT <213> Artificial sequence <220> <223> CDR-L2 (IGMT) for E3 or E3.1 <400> 122 Gly Lys Asn 1 <210> 123 <211> 8 <212> PRT <213> Artificial sequence <220> <223> CDR-H1 (IGMT) for E3 or E3.1 <400> 123 Gly Phe Thr Phe Ser Ser Tyr Ala 1 5 <210> 124 <211> 8 <212> PRT <213> Artificial sequence <220> <223> CDR-H2 (IGMT) of E3 or E3.1 <400> 124 Ile Ser Gly Ser Gly Gly Ser Thr 1 5 <210> 125 <211> 17 <212> PRT <213> Artificial sequence <220> <223> CDR-H3 (IGMT) for E3 or E3.1 <400> 125 Ala Arg Asp Thr Tyr Tyr Tyr Gly Ser Gly Arg Ser Asn Ala Phe Asp 1 5 10 15 Ile <210> 126 <211> 6 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-L1 (IGMT) <400> 126 Gln Asp Ile Ser Asn Tyr 1 5 <210> 127 <211> 3 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-L2 (IGMT) <400> 127 Asp Ala Ser 1 <210> 128 <211> 8 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-H1 (IGMT) <400> 128 Gly Phe Thr Phe Asp Asp Tyr Ala 1 5 <210> 129 <211> 8 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-H2 (IGMT) <400> 129 Ile Ser Trp Asn Ser Gly Ser Ile 1 5 <210> 130 <211> 15 <212> PRT <213> Artificial sequence <220> <223> B3's CDR-H3 (IGMT) <400> 130 Ala Arg Val Gly Asp Ser Ser Gly Trp Ser Asp Ala Phe Asp Ile 1 5 10 15 <210> 131 <211> 6 <212> PRT <213> Artificial sequence <220> <223> A10's CDR-L1 (IGMT) <400> 131 Gln Ser Val Ser Ser Asn 1 5 <210> 132 <211> 3 <212> PRT <213> Artificial sequence <220> <223> A10's CDR-L2 (IGMT) <400> 132 Gly Ala Ser 1 <210> 133 <211> 8 <212> PRT <213> Artificial sequence <220> <223> A10's CDR-H1 (IGMT) <400> 133 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 134 <211> 8 <212> PRT <213> Artificial sequence <220> <223> A10's CDR-H2 (IGMT) <400> 134 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 135 <211> 14 <212> PRT <213> Artificial sequence <220> <223> A10's CDR-H3 (IGMT) <400> 135 Ala Arg Gly Gly Leu Gly Glu Leu Asp Asn Trp Phe Asp Pro 1 5 10 <210> 136 <211> 6 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-L1 (IGMT) <400> 136 Lys Leu Gly Asp Arg Tyr 1 5 <210> 137 <211> 3 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-L2 (IGMT) <400> 137 Lys Asp Ser 1 <210> 138 <211> 8 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-H1 (IGMT) <400> 138 Gly Gly Thr Phe Ser Ser Tyr Gly 1 5 <210> 139 <211> 8 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-H2 (IGMT) <400> 139 Ile Ser Ala Tyr Asn Gly Asn Thr 1 5 <210> 140 <211> 11 <212> PRT <213> Artificial sequence <220> <223> G1's CDR-H3 (IGMT) <400> 140 Ala Arg Val Gly Val Ala Gly Lys Leu Asp Tyr 1 5 10 <210> 141 <211> 9 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-L1 (IGMT) <400> 141 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 142 <211> 3 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-L2 (IGMT) <400> 142 Asp Val Ser 1 <210> 143 <211> 8 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-H1 (IGMT) <400> 143 Gly Tyr Ser Phe Thr Ser Tyr Trp 1 5 <210> 144 <211> 8 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-H2 (IGMT) <400> 144 Ile Tyr Pro Gly Asp Ser Asp Thr 1 5 <210> 145 <211> 13 <212> PRT <213> Artificial sequence <220> <223> G9's CDR-H3 (IGMT) <400> 145 Ala Ser Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val 1 5 10 <210> 146 <211> 6 <212> PRT <213> Artificial sequence <220> <223> H2's CDR-L1 (IGMT) <400> 146 Ser Leu Arg Asn Tyr Tyr 1 5 <210> 147 <211> 3 <212> PRT <213> Artificial sequence <220> <223> H2's CDR-L2 (IGMT) <400> 147 Gly Asn Asn 1 <210> 148 <211> 8 <212> PRT <213> Artificial sequence <220> <223> CDR-H1 (IGMT) of H2 <400> 148 Gly Tyr Thr Phe Thr Ser Tyr Asp 1 5 <210> 149 <211> 8 <212> PRT <213> Artificial sequence <220> <223> CDR-H2 (IGMT) of H2 <400> 149 Ile Ser Ala Tyr Asn Gly Asn Thr 1 5 <210> 150 <211> 10 <212> PRT <213> Artificial sequence <220> <223> CDR-H3 (IGMT) of H2 <400> 150 Ala Arg Asp Gly Gly Asp Ala Phe Asp Ile 1 5 10 <210> 151 <211> 6 <212> PRT <213> Artificial sequence <220> <223> H11's CDR-L1 (IGMT) <400> 151 Ser Leu Arg Ser Tyr Tyr 1 5 <210> 152 <211> 3 <212> PRT <213> Artificial sequence <220> <223> H11's CDR-L2 (IGMT) <400> 152 Gly Arg Asn 1 <210> 153 <211> 8 <212> PRT <213> Artificial sequence <220> <223> H11 CDR-H1 (IGMT) <400> 153 Gly Tyr Thr Phe Thr Ser Tyr Tyr 1 5 <210> 154 <211> 8 <212> PRT <213> Artificial sequence <220> <223> H11 CDR-H2 (IGMT) <400> 154 Ile Asn Pro Ser Gly Gly Ser Thr 1 5 <210> 155 <211> 10 <212> PRT <213> Artificial sequence <220> <223> H11's CDR-H3 (IGMT) <400> 155 Ala Arg Asp Ala Gly Ser Ser Ser Asp Tyr 1 5 10 <210> 156 <211> 9 <212> PRT <213> Artificial sequence <220> <223> F12's CDR-L1 (IGMT) <400> 156 Ser Ser Asp Ile Gly Asp Tyr Asp Tyr 1 5 <210> 157 <211> 3 <212> PRT <213> Artificial sequence <220> <223> F12's CDR-L2 (IGMT) <400> 157 Asp Val Ser 1 <210> 158 <211> 8 <212> PRT <213> Artificial sequence <220> <223> F12's CDR-H1 (IGMT) <400> 158 Gly Tyr Ser Phe Thr Ser Tyr Trp 1 5 <210> 159 <211> 8 <212> PRT <213> Artificial sequence <220> <223> F12's CDR-H2 (IGMT) <400> 159 Ile Tyr Pro Gly Asp Ser Asp Thr 1 5 <210> 160 <211> 13 <212> PRT <213> Artificial sequence <220> <223> F12's CDR-H3 (IGMT) <400> 160 Ala Ser Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val 1 5 10 <210> 161 <211> 6 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-L1 (IGMT) <400> 161 Gln Ser Ile Ser Arg Tyr 1 5 <210> 162 <211> 3 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-L2 (IGMT) <400> 162 Gly Ala Ser 1 <210> 163 <211> 8 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-H1 (IGMT) <400> 163 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 164 <211> 8 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-H2 (IGMT) <400> 164 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 165 <211> 18 <212> PRT <213> Artificial sequence <220> <223> B9's CDR-H3 (IGMT) <400> 165 Ala Arg Gly Glu Ile Ala Val Ala Gln Asn Trp Asp Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 166 <211> 9 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-L1 (IGMT) <400> 166 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 167 <211> 3 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-L2 (IGMT) <400> 167 Asp Val Ser 1 <210> 168 <211> 8 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-H1 (IGMT) <400> 168 Gly Tyr Ser Phe Thr Ser Tyr Trp 1 5 <210> 169 <211> 8 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-H2 (IGMT) <400> 169 Ile Tyr Pro Gly Asp Ser Asp Thr 1 5 <210> 170 <211> 13 <212> PRT <213> Artificial sequence <220> <223> G11's CDR-H3 (IGMT) <400> 170 Ala Ser Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val 1 5 10 <210> 171 <211> 6 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-L1 (IGMT) <400> 171 Ser Leu Arg Arg Tyr Tyr 1 5 <210> 172 <211> 3 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-L2 (IGMT) <400> 172 Gly Gln Asn 1 <210> 173 <211> 8 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-H1 (IGMT) <400> 173 Gly Tyr Thr Phe Thr Ser Tyr Tyr 1 5 <210> 174 <211> 8 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-H2 (IGMT) <400> 174 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 175 <211> 12 <212> PRT <213> Artificial sequence <220> <223> G6's CDR-H3 (IGMT) <400> 175 Ala Arg Gly Trp Gly Tyr Ser Ser Ser Phe Asp Tyr 1 5 10 <210> 176 <211> 8 <212> PRT <213> Artificial sequence <220> <223> F11's CDR-L1 (IGMT) <400> 176 Ser Ser Asn Ile Gly Thr Asn Thr 1 5 <210> 177 <211> 3 <212> PRT <213> Artificial sequence <220> <223> F11's CDR-L2 (IGMT) <400> 177 Ser Asn Asp 1 <210> 178 <211> 8 <212> PRT <213> Artificial sequence <220> <223> F11's CDR-H1 (IGMT) <400> 178 Gly Phe Thr Phe Ser Ser Tyr Ala 1 5 <210> 179 <211> 8 <212> PRT <213> Artificial sequence <220> <223> F11's CDR-H2 (IGMT) <400> 179 Ile Ser Gly Ser Gly Asp Ser Thr 1 5 <210> 180 <211> 12 <212> PRT <213> Artificial sequence <220> <223> F11's CDR-H3 (IGMT) <400> 180 Ala Arg Glu Trp Glu Leu Gly Asp Ala Phe Asp Ile 1 5 10 <210> 181 <211> 6 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-L1 (IGMT) <400> 181 Gln Ser Ile Ser Ser Tyr 1 5 <210> 182 <211> 3 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-L2 (IGMT) <400> 182 Ala Ala Ser 1 <210> 183 <211> 8 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-H1 (IGMT) <400> 183 Gly Ser Thr Phe Ser Ser Tyr Ala 1 5 <210> 184 <211> 8 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-H2 (IGMT) <400> 184 Ile Ser Gly Ser Gly Gly Ser Thr 1 5 <210> 185 <211> 15 <212> PRT <213> Artificial sequence <220> <223> D3's CDR-H3 (IGMT) <400> 185 Ala Lys Asp Arg Gly Ser Tyr Gly Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 186 <211> 6 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-L1 (IGMT) <400> 186 Gln Ser Ile Ser Ser Tyr 1 5 <210> 187 <211> 3 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-L2 (IGMT) <400> 187 Ala Ala Ser 1 <210> 188 <211> 8 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-H1 (IGMT) <400> 188 Gly Tyr Thr Phe Thr Gly Tyr Tyr 1 5 <210> 189 <211> 8 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-H2 (IGMT) <400> 189 Ile Asn Pro Asn Ser Gly Gly Thr 1 5 <210> 190 <211> 15 <212> PRT <213> Artificial sequence <220> <223> B12's CDR-H3 (IGMT) <400> 190 Thr Arg Ala Gly Ala Ser Ile Val Gly Ala Thr Ala Leu Asp Tyr 1 5 10 15 <210> 191 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-L1 (IGMT) <400> 191 Ser Gly Ser Ile Ala Ser Asn Tyr 1 5 <210> 192 <211> 3 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-L2 (IGMT) <400> 192 Glu Asp Asn 1 <210> 193 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-H1 (IGMT) <400> 193 Gly Gly Thr Phe Ser Ser Tyr Thr 1 5 <210> 194 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-H2 (IGMT) <400> 194 Ile Ile Pro Ile Leu Gly Ile Ala 1 5 <210> 195 <211> 14 <212> PRT <213> Artificial sequence <220> <223> E4's CDR-H3 (IGMT) <400> 195 Val Arg Gly Pro Ser Leu Asn Tyr Ala Gly Tyr Phe Asp Asn 1 5 10 <210> 196 <211> 6 <212> PRT <213> Artificial sequence <220> <223> E12's CDR-L1 (IGMT) <400> 196 Ser Leu Arg Ser Tyr Tyr 1 5 <210> 197 <211> 3 <212> PRT <213> Artificial sequence <220> <223> E12's CDR-L2 (IGMT) <400> 197 Gly Lys Glu 1 <210> 198 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E12's CDR-H1 (IGMT) <400> 198 Gly Phe Thr Phe Ser Ser Tyr Ala 1 5 <210> 199 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E12's CDR-H2 (IGMT) <400> 199 Ile Ser Tyr Asp Gly Ser Asn Lys 1 5 <210> 200 <211> 10 <212> PRT <213> Artificial sequence <220> <223> E12's CDR-H3 (IGMT) <400> 200 Ala Arg Glu Arg Gly Ser Gly Met Asp Val 1 5 10 <210> 201 <211> 6 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-L1 (IGMT) <400> 201 Gln Asp Ile Asp Asp Asp 1 5 <210> 202 <211> 3 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-L2 (IGMT) <400> 202 Glu Ala Ser 1 <210> 203 <211> 8 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-H1 (IGMT) <400> 203 Gly Tyr Thr Phe Thr Ser Tyr Gly 1 5 <210> 204 <211> 8 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-H2 (IGMT) <400> 204 Ile Asn Pro Asn Ser Gly Gly Thr 1 5 <210> 205 <211> 10 <212> PRT <213> Artificial sequence <220> <223> D1's CDR-H3 (IGMT) <400> 205 Ala Ser Arg Gly Val Asp Glu Gly Asp Tyr 1 5 10 <210> 206 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-L1 (IGMT) <400> 206 Ser Gly Asn Ile Ala Ser Asn Tyr 1 5 <210> 207 <211> 3 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-L2 (IGMT) <400> 207 Arg Asp Asp 1 <210> 208 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-H1 (IGMT) <400> 208 Gly Tyr Thr Phe Thr Thr Tyr Asp 1 5 <210> 209 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-H2 (IGMT) <400> 209 Met Asn Pro Asn Ser Gly Asn Ser 1 5 <210> 210 <211> 17 <212> PRT <213> Artificial sequence <220> <223> E6's CDR-H3 (IGMT) <400> 210 Ala Thr Gly Asp Tyr Ser Gly Val Val Leu Thr Ala Thr Ala Leu Asp 1 5 10 15 Tyr <210> 211 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-L1 (IGMT) <400> 211 Ser Ser Asn Ile Gly Asn Asn Tyr 1 5 <210> 212 <211> 3 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-L2 (IGMT) <400> 212 Arg Asn Asn 1 <210> 213 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-H1 (IGMT) <400> 213 Gly Phe Thr Phe Ser Ser Tyr Gly 1 5 <210> 214 <211> 8 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-H2 (IGMT) <400> 214 Ile Lys Gln Asp Gly Ser Glu Lys 1 5 <210> 215 <211> 16 <212> PRT <213> Artificial sequence <220> <223> E9's CDR-H3 (IGMT) <400> 215 Ala Arg Glu Asp Arg Ile Ala Ala Ala Gly Met Arg Glu Leu Asp Tyr 1 5 10 15 <210> 216 <211> 11 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-L1 (IGMT) <400> 216 Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr 1 5 10 <210> 217 <211> 3 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-L2 (IGMT) <400> 217 Leu Gly Ser 1 <210> 218 <211> 8 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-H1 (IGMT) <400> 218 Gly Phe Ser Phe Thr Ser Tyr Ala 1 5 <210> 219 <211> 8 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-H2 (IGMT) <400> 219 Ile Ser Ser Asp Gly Thr Thr Thr 1 5 <210> 220 <211> 13 <212> PRT <213> Artificial sequence <220> <223> A11's CDR-H3 (IGMT) <400> 220 Ala Arg Asp Gln Leu Leu Gly Trp Asp Ala Leu Asn Val 1 5 10 <210> 221 <211> 116 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (E3) <400> 221 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Asn Phe Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Met Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Ser His 85 90 95 Leu Thr Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala 115 <210> 222 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain Variable Region (E3 or E3.1) <400> 222 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ile Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Thr Tyr Tyr Tyr Gly Ser Gly Arg Ser Asn Ala Phe Asp 100 105 110 Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 223 <211> 110 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (B3) <400> 223 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Phe 85 90 95 Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Ala Ala Ala 100 105 110 <210> 224 <211> 122 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region (B3) <400> 224 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Gly Asp Ser Ser Gly Trp Ser Asp Ala Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 225 <211> 114 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (A10) <400> 225 Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Arg 85 90 95 Met Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Ala 100 105 110 Ala Ala <210> 226 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain Variable Region (A10) <400> 226 Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Leu Gly Glu Leu Asp Asn Trp Phe Asp Pro Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 227 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Light chain variable region (G1) <400> 227 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Leu Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Tyr Lys Leu Gly Asp Arg Tyr Val 20 25 30 Ser Trp Tyr Gln Gln Lys Thr Gly Gln Ser Pro Val Val Val Ile Tyr 35 40 45 Lys Asp Ser Gln Arg Pro Ser Gly Val Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Gly Thr Gly Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Ala Ala Ala 100 105 110 <210> 228 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain Variable Region (G1) <400> 228 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Glu Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Gly Val Ala Gly Lys Leu Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 229 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Light Chain Variable Region (B9) <400> 229 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr His Cys Gln Gln Ala Tyr Gly Phe Pro Leu 85 90 95 Thr Leu Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Ala Ala Ala 100 105 110 <210> 230 <211> 125 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region (B9) <400> 230 Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Glu Ile Ala Val Ala Gln Asn Trp Asp Tyr Tyr Gly Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 231 <211> 114 <212> PRT <213> Synthetic sequence <220> <223> Light chain variable region (H11) <400> 231 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Ala Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Ile Tyr 35 40 45 Gly Arg Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asp Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Ala 100 105 110 Ala Ala <210> 232 <211> 117 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region (H11) <400> 232 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ala Gly Ser Ser Ser Asp Tyr Trp Gly Arg Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 233 <211> 118 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (G9) <400> 233 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Met Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Gly Ser 85 90 95 Ser Thr Leu Asp Val Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 Gly Gln Pro Ala Ala Ala 115 <210> 234 <211> 120 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region (G9) <400> 234 Gln Val Gln Leu Val Gln Pro Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Ser Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 235 <211> 114 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (H2) <400> 235 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Asn Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Ser 35 40 45 Gly Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asp Thr Ala Ser Leu Thr Ile Ser Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Leu Asp Ser Thr Tyr Asn His 85 90 95 Pro Ile Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro Ala 100 105 110 Ala Ala <210> 236 <211> 117 <212> PRT <213> Synthetic Sequence <220> <223> Heavy Chain Variable Region (H2) <400> 236 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asp Ile His Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 237 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> Light Chain Variable Region (F12) <400> 237 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Ile Gly Asp Tyr 20 25 30 Asp Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Thr Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Arg Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Thr Ser Ser 85 90 95 Ser Val Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala 115 <210> 238 <211> 120 <212> PRT <213> Synthetic Sequence <220> <223> Heavy Chain Variable Region (F12) <400> 238 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Ser Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 239 <211> 117 <212> PRT <213> Synthetic Sequence <220> <223> Light Chain Variable Region (G11) <400> 239 Gln Ser Ala Leu Thr Gln Pro Arg Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ser Ser Ser 85 90 95 Ser Thr Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Ala Ala Ala 115 <210> 240 <211> 120 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region (G11) <400> 240 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Ser Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 241 <211> 114 <212> PRT <213> Synthetic sequence <220> <223> Light chain variable region (G6) <400> 241 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Thr Ile Thr Cys Gln Gly Asp Ser Leu Arg Arg Tyr Tyr Ala 20 25 30 Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Gln Asn Tyr Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Thr Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Ala 100 105 110 Ala Ala <210> 242 <211> 119 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region (G6) <400> 242 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Trp Gly Tyr Ser Ser Ser Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Val Thr Val Ser Ser 115 <210> 243 <211> 116 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (F11) <400> 243 Gln Ser Val Leu Thr Gln Pro Pro Ser Thr Ser Gly Thr Pro Gly Gln 1 5 10 15 Thr Phe Ser Ile Phe Cys Ser Gly Ser Ser Ser Asn Ile Gly Thr Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Glu Thr Trp Asp Asp Ser Leu 85 90 95 Lys Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala 115 <210> 244 <211> 119 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region (F11) <400> 244 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Gly Ser Gly Asp Ser Thr Tyr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Trp Glu Leu Gly Asp Ala Phe Asp Ile Trp Gly Arg Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 245 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (D3) <400> 245 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Arg Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Ala Ala Ala 100 105 110 <210> 246 <211> 122 <212> PRT <213> Synthetic Sequence <220> <223> Heavy Chain Variable Region (D3) <400> 246 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Arg Gly Ser Tyr Gly Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 247 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Light chain variable region (B12) <400> 247 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Arg 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Ala Ala Ala 100 105 110 <210> 248 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain Variable Region (B12) <400> 248 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ala Gly Ala Ser Ile Val Gly Ala Thr Ala Leu Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 249 <211> 118 <212> PRT <213> Synthetic Sequence <220> <223> Light Chain Variable Region (E4) <400> 249 Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 1 5 10 15 Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn 20 25 30 Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val 35 40 45 Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 65 70 75 80 Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr 85 90 95 Gly Asn Arg Asn Tyr Val Phe Gly Thr Gly Thr Gln Leu Thr Val Leu 100 105 110 Gly Gln Pro Ala Ala Ala 115 <210> 250 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain Variable Region (E4) <400> 250 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Met Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Tyr Asp Asp Thr Ala Val Tyr Phe Cys 85 90 95 Val Arg Gly Pro Ser Leu Asn Tyr Ala Gly Tyr Phe Asp Asn Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 251 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> Light Chain Variable Region (E12) <400> 251 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Glu Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Arg Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Gly Ser Thr Thr Asp Tyr 85 90 95 Met Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Gly Gln Pro Ala 100 105 110 Ala Ala <210> 252 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain Variable Region (E12) <400> 252 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg Gly Ser Gly Met Asp Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 253 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (D1) <400> 253 Glu Thr Thr Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Thr Pro Gly 1 5 10 15 Asp Lys Val Asn Ile Ser Cys Lys Ala Ser Gln Asp Ile Asp Asp Asp 20 25 30 Met Asn Trp Tyr Gln Gln Lys Pro Gly Glu Ala Ala Ile Ser Ile Ile 35 40 45 Gln Glu Ala Ser Thr Leu Val Pro Gly Ile Pro Pro Arg Phe Ser Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser 65 70 75 80 Glu Asp Ala Ala Tyr Tyr Phe Cys Leu Gln His Asp Lys Phe Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Ala Ala Ala 100 105 110 <210> 254 <211> 117 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region (D1) <400> 254 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Arg Gly Val Asp Glu Gly Asp Tyr Trp Gly Gln Gly Thr Met 100 105 110 Val Thr Val Ser Ser 115 <210> 255 <211> 116 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (E6) <400> 255 Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 1 5 10 15 Thr Val Thr Leu Ser Cys Thr Gly Ser Ser Gly Asn Ile Ala Ser Asn 20 25 30 Tyr Val Gln Trp Tyr Gln His Arg Pro Gly Ser Ala Pro Thr Thr Val 35 40 45 Ile Tyr Arg Asp Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 65 70 75 80 Leu Arg Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser 85 90 95 Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala 115 <210> 256 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain Variable Region (E6) <400> 256 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Asp Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Met Asn Pro Asn Ser Gly Asn Ser Arg Ser Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Ser Met Thr Ser Asp Ser Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Gly Asp Tyr Ser Gly Val Val Leu Thr Ala Thr Ala Leu Asp 100 105 110 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 257 <211> 116 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (E9) <400> 257 Gln Ser Glu Leu Thr Gln Leu Pro Ser Ala Ser Glu Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala 115 <210> 258 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain Variable Region (E9) <400> 258 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Arg Ile Ala Ala Ala Gly Met Arg Glu Leu Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 259 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Light Chain Variable Region (A11) <400> 259 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys Arg Thr Ala Ala Ala 115 <210> 260 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain Variable Region (A11) <400> 260 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Glu Gln Pro Gly Gly 1 5 10 15 Phe Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Thr Ser Tyr 20 25 30 Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Ser Asp Gly Thr Thr Thr Thr Tyr Ala Asp Ser Val 50 55 60 Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gln Leu Leu Gly Trp Asp Ala Leu Asn Val Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 261 <211> 348 <212> DNA <213> The snowstorm <220> <223> Entertainment Equipment(E3) Copyright <400> 261 tcctatgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc acatgccagg gagacagcct cagaaacttt tatgcaagct ggtaccagca gaagtcagga caggccccag ttcttgtcat gtatggtaaa aacaaccggc cctcagggat cccagaccga ttctctggct ccacctcagg aaacacagct tccttgacca tcactggggc tcaggcgga gatgaggctg actattactg taactcccgg gacagcagtg gtagccattt gacgggcgta ttcggcggag ggaccaaggt caccgtccta ggtcagcccg cggccgca 348 <210> 262 <211> 372 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (E3 or E3.1) encoding gene <400> 262 caggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagc agctatgcca tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcagct attagtggta gtggtggtag cacatactac 180 gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa tacgctgtat 240 ctgcaaatga ttagcctgag agctgaggac acggctgtgt attactgtgc gagagatacg 300 tattactatg gttcggggag aagtaatgct tttgatatat ggggccaggg aaccctggtc 360 accgtctcga gt 372 <210> 263 <211> 330 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (B3) encoding gene <400> 263 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc aggcgagtca ggacattagc aactatttga attggtatca gcagaaacca 120 gggaaagccc ctaagctcct gatctacgat gcatccaatt tggaaacagg ggtcccatca 180 aggttcagtg gaagtggatc tgggacagat tttactttca ccatcagcag cctgcagcct 240 gaagatattg caacatatta ctgtcaacag tatgataatc tccctttcgg cggagggacc 300 aaagtggata tcaaacgtac cgcggccgca 330 <210> 264 <211> 366 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (B3) coding gene <400> 264 gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct 120 ccagggaagg gcctggagtg ggtctcaggt attagttgga atagtggtag cataggctac 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 cttcaaatga acagtctgag agccgaggac acggccgtgt attactgtgc gagagttggg 300 gatagcagtg gctggtccga tgcttttgat atctggggcc aagggacaat ggtcaccgtc 360 tcgagt 366 <210> 265 <211> 342 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (A10) encoding gene <400> 265 gatattgtga tgacacagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60 ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 120 ggccaggctc ccaggctcct catctatggt gcatccacca gggccaccgg tatcccagcc 180 aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240 gaagattttg cagtttatta ctgtcagcag tatggtagct cacctcggat gtacactttt 300 ggccagggga ccaaagtgga tatcaaacgt accgcggccg ca 342 <210> 266 <211> 363 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (A10) encoding gene <400> 266 caaatgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60 tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggtggg atcatcccta tctttggtac agcaaactac 180 gcacagaagt tccagggcag agtcacgatt accgcggaca aatccatcag cacagcctac 240 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaggcggc 300 ctcggggagt tggacaactg gttcgacccc tggggccagg gaaccctggt caccgtctcg 360 agt 363 <210> 267 <211> 336 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (G1) encoding gene <400> 267 tcctatgagc tgactcagcc accctcactg tccgtgtccc caggacagac agccagcatc 60 acctgctcag gatataaact gggagataga tatgtttcct ggtatcagca gaagacaggc 120 cagtcccctg tggtggtcat ctataaagat agccagcggc cctcaggggt ccctgaacga 180 ttctctggct ccaactctgg gaacacagcc actctgacca tcagcgggac ccaggctatg 240 gatgaggctg actattactg tcaggcgtgg gacagcggca ctggggtatt cggcggaggg 300 accaagctga ccgtcctagg tcagcccgcg gccgca 336 <210> 268 <211> 354 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (G1) encoding gene <400> 268 gaagtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60 tcctgcaagg cttctggagg caccttcagc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180 gcacaggagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctat 240 atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagtaggg 300 gtggctggta aacttgacta ctggggccaa ggaaccctgg tcaccgtctc gagt 354 <210> 269 <211> 354 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (G9) encoding gene <400> 269 cagtctgcgc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcactg gaagcagcag tgacgttggt ggttataact atgtctcctg gtaccagcaa 120 cacccaggca aagcccccaa actcatgatt tatgatgtca gtaatcggcc ctcaggggtt 180 tctgatcgct tctctggctc caagtctggc aacatggcct ccctgaccat ctctgggctc 240 caggctgagg acgaggctga ttattactgc agctcatata caggaagcag cactctcgac 300 gtgctattcg gcggagggac caagctgacc gtcctaggtc agcccgcggc cgca 354 <210> 270 <211> 360 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (G9) encoding gene <400> 270 caggtgcagc tggtgcagcc tggagcagag gtgaaaaagc cgggggagtc tctgaagatc 60 tcctgtaagg gttctggata cagctttacc agctactgga tcggctgggt gcgccagatg 120 cccgggaagg gcctggagtg gatggggatc atctatcctg gtgactctga taccagatac 180 agcccgtcct tccaaggcca ggtcaccatc tcagccgaca agtccatcag caccgcctac 240 ctgcagtgga gcagcctgaa ggcctcggac accgccatgt attactgtgc gagtcaatat 300 tacgatgggg gttactacat ggacgtctgg ggccagggaa ccctggtcac cgtctcgagt 360 360 <210> 271 <211> 342 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (H2) encoding genes <400> 271 tcctatgagc tgactcagga ccctgctgtg tcggtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaaactat tatgcaagct ggtaccagca gaagccagga 120 caggccccta ttcttgtcat ctctggtaac aacaaacggc cctcggggat cccagaccga 180 ttctctggct ccagctcagg agacacagct tccttgacca tctctggggc tcaggcggaa 240 gatgaggctg actattactg taactcccta gacagcactt ataaccatcc gatattcggc 300 ggagggacca aggtcaccgt cctaggtcag cccgcggccg ca 342 <210> 272 <211> 351 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (H2) encoding genes <400> 272 caggtccagc ttgtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggata caccttcacc agttatgata tccactgggt gcgacaggcc 120 actggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180 gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagatggg 300 ggtgatgctt ttgatatctg gggccaagga accctggtca ccgtctcgag t 351 <210> 273 <211> 342 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (H11) encoding gene <400> 273 tcctatgagc tgactcagga ccctgctgcg tctgtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaagctat tatgcaagct ggtaccagca gaagccagga 120 caggcccctg tagttgtcat ctatggtaga aacaaccggc cctcagggat cccagaccga 180 ttctctggct ccagctcagg agacacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taagtcccgg gacagcagtg gtaaccatta tgtcttcgga 300 actgggacca agctgaccgt cctaggtcag cccgcggccg ca 342 <210> 274 <211> 351 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (H11) encoding gene <400> 274 caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60 tcctgcaagg catctggata caccttcacc agctactata tgcactgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggaata atcaacccta gtggtggtag cacaagctac 180 gcacagaagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac 240 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagatgcc 300 ggcagctcgt ccgattactg gggccgtggc accctggtca ccgtctcgag t 351 <210> 275 <211> 348 <212> DNA <213> Artificial Sequence <220> <223> Light chain variable region (F12) encoding gene <400> 275 cagtctgtgc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60 tcctgcgctg gaaccagcag tgacattggt gattatgact atgtctcctg gtaccaacag 120 cacccaggca agactcccaa actcatgatt tatgatgtca gtaggcggcc ctcaggggtc 180 cctgatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240 cagactgagg acgaggctga ttattactgc gcctcatata caagcagcag cgtcgtggtc 300 ttcggcggag ggaccaagct gaccgtccta ggtcagcccg cggccgca 348 <210> 276 <211> 360 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (F12) encoding gene <400> 276 caggtgcagc tggtgcagtc tggagcagag gtgaaaaagc ccggggagtc tctgaagatc 60 tcctgtaagg gttctggata cagctttacc agctactgga tcggctgggt gcgccagatg 120 cccgggaaag gcctggagtg gatggggatc atctatcctg gtgactctga taccagatac 180 agcccgtcct tccaaggcca ggtcaccatc tcagccgaca agtccatcag caccgcctac 240 ctgcagtgga gcagcctgaa ggcctcggac accgccatgt attactgtgc gagtcaatat 300 tacgatgggg gttactacat ggacgtctgg ggccagggca ccctggtcac cgtctcgagt 360 360 <210> 277 <211> 336 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (B9) encoding gene <400> 277 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc gggcaagtca gagcattagc aggtatttaa attggtatca gcagaaacca 120 gggaaagccc ccaagctcct gatctatggt gcatccagtt tgcaaagtgg ggtcccatca 180 aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcagcct 240 gaagatttcg caacttacca ttgtcaacag gcttacggtt tccccctcac tctcggcgga 300 gggaccaagg tggagatcaa acgtaccgcg gccgca 336 <210> 278 <211> 375 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (B9) encoding gene <400> 278 caggtgcagc tggtggagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60 tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac 180 gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac 240 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaggggaa 300 atagcagtgg ctcaaaactg ggactactac ggtatggacg tctggggcca gggcaccctg 360 gtcaccgtct cgagt 375 <210> 279 <211> 351 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (G11) encoding gene <400> 279 cagtctgcgc tgactcagcc tcgctcagtg tccgggtctc ctggacagtc agtcaccatc 60 tcctgcactg gaaccagcag tgatgttggt ggttataact atgtctcctg gtaccaacag 120 cacccaggca aagcccccaa actcatgatt tatgatgtca gtaagcggcc ctcaggggtc 180 cctgatcgct tctctggctc caagtctggc aacacggcct ccctgacaat ctctgggctc 240 caggctgagg acgaggctga ttattactgc agctcatatt caagcagcag cactctcgtg 300 gttttcggcg gagggaccaa gctgaccgtc ctaggtcagc ccgcggccgc a 351 <210> 280 <211> 360 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (G11) encoding gene <400> 280 caggtccagc tggtacagtc tggagcagag gtgaaaaagc cgggggagtc tctgaagatc 60 caggtccagc tggtacagtc tggagcagag gtgaaaaagc cgggggagtc tctgaagatc 60 tcctgtaagg gttctggata cagctttacc agctactgga tcggctgggt gcgccagatg 120 tcctgtaagg gttctggata cagctttacc agctactgga tcggctgggt gcgccagatg 120 cccgggaaag gcctggagtg gatggggatc atctatcctg gtgactctga taccagatac 180 cccgggaaag gcctggagtg gatggggatc atctatcctg gtgactctga taccagatac 180 agcccgtcct tccaaggcca ggtcaccatc tcagccgaca agtccatcag caccgcctac 240 agcccgtcct tccaaggcca ggtcaccatc tcagccgaca agtccatcag caccgcctac 240 ctgcagtgga gcagcctgaa ggcctcggac accgccatgt attactgtgc gagtcaatat 300 ctgcagtgga gcagcctgaa ggcctcggac accgccatgt attactgtgc gagtcaatat 300 tacgatgggg gttactacat ggacgtctgg ggccagggaa ccctggtcac cgtctcgagt 360 tacgatgggg gttactacat ggacgtctgg ggccagggaa ccctggtcac cgtctcgagt 360 360 360 <210> 281<210> 281 <211> 342<211> 342 <212> DNA<212> DNA <213> 人工序列<213> Artificial sequence <220> <220> <223> 轻链可变区(G6)编码基因 <223> Light chain variable region (G6) encoding gene <400> 281 <400> 281 tcctatgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcacgatc 60 tcctatgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcacgatc 60 acatgccaag gagacagcct cagaaggtat tatgcaacct ggtaccagca gaagccagga 120 acatgccaag gagacagcct cagaaggtat tatgcaacct ggtaccagca gaagccagga 120 caggcccctg tccttgtcat ctatggtcaa aactaccggc cctcggggat cccagaccga 180 caggcccctg tccttgtcat ctatggtcaa aactaccggc cctcggggat cccagaccga 180 ttctctggct ccaactcagg aaccacagct tccttgacca tcactggggc tcaggcggaa 240 ttctctggct ccaactcagg aaccacagct tccttgacca tcactggggc tcaggcggaa 240 gatgaggctg actattactg taactcccgg gacagcagtg gtaaccatgt ggtattcggc 300 ggagggacca agctgaccgt cctaggtcag cccgcggccg ca 342 <210> 282 <211> 357 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (G6) encoding gene <400> 282 gaggtgcagc tggtggagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60 tcctgcaagg catctggata caccttcacc agctactata tgcactgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac 180 gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac 240 atggagctga gcagcctgag atctgaggac acggccgtgt actactgtgc gagagggtgg 300 gggtatagca gctcgtttga ctactggggg caagggacca cggtcaccgt ctcgagt 357 <210> 283 <211> 348 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (F11) encoding gene <400> 283 cagtctgtgc tgactcagcc accctcaacg tctgggaccc ccgggcagac gttctccatt 60 ttttgttctg gaagcagttc gaacatcgga actaatactg ttaattggta ccagcagctc 120 ccaggaacgg cccccaaact cctcatctat agtaatgatc agcggccctc aggggtccct 180 gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag 240 tctgaggatg aggctgatta ttactgtgaa acatgggatg acagcctgaa aggcccggtg 300 ttcggcgggg ggaccaaggt caccgtccta ggtcagcccg cggccgca 348 <210> 284 <211> 357 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (F11) encoding gene <400> 284 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgaaactc 60 tcctgtgcag cgtctggatt cacctttagc agctatgcca tgagctgggt ccgccgggct 120 ccagggaagg ggctggagtg ggtctcaact attagtggta gtggtgatag cacatactac 180 gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acaacctgag agccgaggac acggccgtat attactgtgc gagagaatgg 300 gaactaggcg atgcttttga tatctggggc cgtggcaccc tggtcaccgt ctcgagt 357 <210> 285 <211> 336 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (D3) encoding gene <400> 285 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca 120 gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180 aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240 gaagattttg caacttacta ctgtcaacag agttacagta cccggtggac gttcggccaa 300 gggaccaagg tggaaatcaa acgtaccgcg gccgca 336 <210> 286 <211> 366 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (D3) encoding gene <400> 286 gaggtgcagc tgttggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cctctggatc cacctttagc agctatgcca tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcagct attagtggta gtggtggtag cacatactac 180 gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagacaga 300 ggcagctatg gttactacta cggtatggac gtctggggcc aagggacaat ggtcaccgtc 360 tcgagt 366 <210> 287 <211> 336 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (B12) encoding gene <400> 287 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca 120 gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180 aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240 gaagattttg caacttacta ctgtcaacag agttacagta ccctccggac gttcggccaa 300 gggaccaagg tggagatcaa acgtaccgcg gccgca 336 <210> 288 <211> 366 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (B12) encoding gene <400> 288 caggtccagc tggtacagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggata caccttcacc ggctactata tgcactgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcaacccta acagtggtgg cacaaactac 180 gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac 240 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtac gagagccggt 300 gcttctatag tgggagctac cgcgcttgac tactggggcc agggaaccct ggtcaccgtc 360 tcgagt 366 <210> 289 <211> 354 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (E4) encoding gene <400> 289 aattttatgc tgactcagcc ccactctgtg tcggagtctc cgggaaagac ggtaaccatc 60 tcctgcaccc gcagcagtgg cagcattgcc agcaactatg tgcagtggta ccagcagcgc 120 ccgggcagtt cccccaccac tgtgatctat gaggataacc aaagaccctc tggggtccct 180 gatcggttct ctggctccat cgacagctcc tccaactctg cctccctcac catctctgga 240 ctgaagactg aggacgaggc tgactactac tgtcagtctt atgataccgg caatcggaat 300 tatgtcttcg gaactgggac ccagctcacc gtcctaggtc agcccgcggc cgca 354 <210> 290 <211> 363 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (E4) encoding gene <400> 290 caggtgcagc tggtgcaatc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60 tcctgcaagg cttctggagg caccttcagc agctatacta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggaagg atcatcccta tccttggtat agcaaactac 180 gcacagaagt tccagggcag agtcaccatg accagggaca tgtccacaga cacagcctac 240 atggagttga gcagcctgac atatgatgac acggccgtat atttttgtgt gagaggccct 300 agtcttaatt atgccggcta ttttgacaac tggggccagg gcaccctggt caccgtctcg 360 agt 363 <210> 291 <211> 342 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (E12) encoding gene <400> 291 tcctatgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60 acatgccaag gagacagcct cagaagctat tatgcaagct ggtaccagca gaagtcagga 120 caggcccctg tacttgtcat ctatggtaaa gaaaagcgcc cctcagggat cccagaccga 180 ttctctggct ccagctcagg aaacacagct tccttgacca tcactggggc tcgggcggaa 240 gatgaggctg actattactg taactcccgg ggcagcacta ctgactatat ggtgttcggc 300 gggggaccc agctcaccgt cctaggtcag cccgcggccg ca 342 <210> 292 <211> 351 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (E12) encoding gene <400> 292 caggtgcagc tggtggagtc cgggggaggc ttagttcagc ctggggggtc cctgagactc 60 caggtgcagc tggtggagtc cgggggaggc ttagttcagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt caccttcagt agctatgcta tgcactgggt ccgccaggct 120 tcctgtgcag cctctggatt caccttcagt agctatgcta tgcactgggt ccgccaggct 120 ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagcaa taaatactac 180 ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagcaa taaatactac 180 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gagagaacgg 300 ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gagagaacgg 300 ggaagtggta tggacgtctg gggccaagga accctggtca ccgtctcgag t 351 ggaagtggta tggacgtctg gggccaagga accctggtca ccgtctcgag t 351 <210> 293<210> 293 <211> 336<211> 336 <212> DNA<212> DNA <213> 人工序列<213> Artificial sequence <220> <220> <223> 轻链可变区(D1)编码基因 <223> Light chain variable region (D1) encoding gene <400> 293 <400> 293 gaaacgacac tcacgcagtc tccagcattc atgtcagcga ctccaggaga caaagtcaac 60 gaaacgacac tcacgcagtc tccagcattc atgtcagcga ctccaggaga caaagtcaac 60 atctcctgca aagccagcca agacattgat gatgatatga actggtacca acagaaacca 120 atctcctgca aagccagcca agacattgat gatgatatga actggtacca acagaaacca 120 ggagaagctg ctatttccat tattcaagaa gctagtactc tcgttcctgg aatcccacct 180 ggagaagctg ctatttccat tattcaagaa gctagtactc tcgttcctgg aatcccacct 180 cgattcagtg gcagcgggta tggaacagat tttaccctca caattaataa catagaatct 240 cgattcagtg gcagcgggta tggaacagat tttaccctca caattaataa catagaatct 240 gaggatgctg catattactt ctgtctacaa catgataagt tcccgtacac ttttggccag 300 gggaccaagc tggagatcaa acgtaccgcg gccgca 336 <210> 294 <211> 351 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (D1) encoding gene <400> 294 gaagtgcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggtta cacctttacc agctatggta tcagctgggt gcgacaggcc 120 cctggacaag ggcttgagtg gatgggatgg atcaacccta acagtggtgg cacaaactat 180 gcacagaagt ttcagggcag ggtcaccatg accagggaca cgtccatcag cacagcctac 240 atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagtcggggg 300 gttgatgagg gggactactg gggccaaggg acaatggtca ccgtctcgag t 351 <210> 295 <211> 348 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (E6) encoding gene <400> 295 aattttatgc tgactcagcc ccactctgtg tcggagtctc cggggaagac ggttaccctc 60 tcctgcaccg gcagcagcgg caacattgcc agtaactatg tgcagtggta ccagcaccgc 120 ccgggcagtg cccccaccac tgtgatctac cgggatgacc aaagaccctc tggagtccct 180 gatcgcttct ctggctccat cgacagttca tccaactctg cctccctcac gatctctgga 240 ctgaggcctg aggacgaggc tgactattac tgtcagtctt atgatagcag ctcttgggtg 300 ttcggcggag ggaccaagct gaccgtccta ggtcagcccg cggccgca 348 <210> 296 <211> 372 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (E6) encoding gene <400> 296 caggtccagc ttgtgcagtc tggagcagag gtgaagaagc ctggggcctc agtgaaggtc 60 tcctgcaagg cttctggata caccttcacc acttatgata tcacctgggt gcgacaggcc 120 cctggacaag gccttgagtg gatgggatgg atgaacccga acagtggtaa ctcacgctct 180 gcacagaagt tccagggcag agtcagcatg accagtgact cctccataag cacagcctac 240 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc aacaggagac 300 tactcgggtg tggtactaac tgcaacagca cttgactact ggggccaggg aaccctggtc 360 accgtctcga gt 372 <210> 297 <211> 348 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (E9) encoding gene <400> 297 cagtctgagc tgactcagct accctcagcg tctgagaccc ccgggcagag ggtcaccatc 60 tcttgttctg gaagcagctc caacatcgga aataattatg tatactggta ccagcaactc 120 cccggaacgg cccccaaact cctcatctat aggaataatc agcggccctc aggggtccct 180 gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccgg 240 tccgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgag tggttgggtg 300 ttcggcggag ggaccaagct gaccgtccta ggtcagcccg cggccgca 348 <210> 298 <211> 369 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (E9) encoding gene <400> 298 caggtgcagc tggtggagtc tgggggaggc ttggtacagc ctgggaggtc cctgagactc 60 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtggccaac ataaagcaag atggaagtga gaaatactat 180 gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa cacgctgtat 240 ctccaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gagagaggac 300 cgtatagcag cagctgggat gcgggagttg gactactggg gccagggcac cctggtcacc 360 gtctcgagt 369 <210> 299 <211> 354 <212> DNA <213> Artificial sequence <220> <223> Light chain variable region (A11) encoding gene <400> 299 gatattgtga tgacccagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120 tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taaccgggcc 180 tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240 agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggcct 300 ccgtacacct ttggccaggg gaccaaggtg gagatcaaac gtaccgcggc cgca 354 <210> 300 <211> 360 <212> DNA <213> Artificial sequence <220> <223> Heavy chain variable region (A11) encoding gene <400> 300 gaggtgcagc tgttggagtc tgggggaggc ttggaacagc ctggggggtt cctgagactc 60 tcctgtgcag cctctggatt ctcctttacc agctacgcca tgacctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcaggt attagtagtg atgggaccac tacaacctac 180 gcggactccg tgaggggccg gttcaccatc tccagagaca acgccaagaa cacggtgtat 240 ctccaaatga acagtctgag agacgaggac acggctgtgt attattgtgc aagagatcaa 300 ttgttgggct gggatgctct gaatgtctgg ggccaaggga caatggtcac cgtctcgagt 360 360 <210> 301 <211> 216 <212> PRT <213> Artificial sequence <220> <223> Light chain (E3) <400> 301 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Asn Phe Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Met Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Ser His 85 90 95 Leu Thr Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 302 <211> 451 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (E3 or E3.1) <400> 302 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ile Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Thr Tyr Tyr Tyr Gly Ser Gly Arg Ser Asn Ala Phe Asp 100 105 110 Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu 130 135 140 Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn 195 200 205 Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser 210 215 220 Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln 260 265 270 Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Leu Gly Lys 450 <210> 303 <211> 212 <212> PRT <213> Artificial sequence <220> <223> Light chain (B3) <400> 303 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Phe 85 90 95 Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Ala Ala Ala Pro Ser 100 105 110 Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala 115 120 125 Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val 130 135 140 Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser 145 150 155 160 Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr 165 170 175 Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Leu Tyr Ala Cys 180 185 190 Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 195 200 205<00043<400> 304 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Gly Asp Ser Ser Gly Trp Ser Asp Ala Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr 210 215 220 Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 260 265 270 Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 Lys <210> 305 <211> 216 <212> PRT <213> Synthetic Sequence <220> <223> Light Chain (A10) <400> 305 Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Arg 85 90 95 Met Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Ala 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 145 150 155 160 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Leu Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 306 <211> 448 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (A10) <400> 306 Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Leu Gly Glu Leu Asp Asn Trp Phe Asp Pro Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 307 <211> 212 <212> PRT <213> Artificial sequence <220> <223> Light chain (G1) <400> 307 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Leu Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Tyr Lys Leu Gly Asp Arg Tyr Val 20 25 30 Ser Trp Tyr Gln Gln Lys Thr Gly Gln Ser Pro Val Val Val Ile Tyr 35 40 45 Lys Asp Ser Gln Arg Pro Ser Gly Val Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Gly Thr Gly Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Ala Ala Ala 100 105 110 Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn 115 120 125 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 130 135 140 Thr Val Ala Trp Lys Glu Asp Ser Ser Pro Val Lys Ala Gly Val Glu 145 150 155 160 Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser 165 170 175 Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser 180 185 190 Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro 195 200 205 Thr Glu Cys Ser 210 <210> 308 <211> 445 <212> PRT <213> Synthetic Sequence <220> <223> Heavy Chain (G1) <400> 308 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Glu Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Gly Val Ala Gly Lys Leu Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln 260 265 270 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320 Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 340 345 350 Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400 Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410 415 Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425 430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 309 <211> 218 <212> PRT <213> Synthetic Sequence <220> <223> Light Chain (G9) <400> 309 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Met Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Gly Ser 85 90 95 Ser Thr Leu Asp Val Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 Gly Gln Pro Ala Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 115 120 125 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 130 135 140 Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 145 150 155 160 Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn 165 170 175 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 180 185 190 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 195 200 205 Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 310 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (G9) <400> 310 Gln Val Gln Leu Val Gln Pro Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Ser Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 311 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Light chain (H2) <400> 311 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Asn Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Ser 35 40 45 Gly Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asp Thr Ala Ser Leu Thr Ile Ser Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Leu Asp Ser Thr Tyr Asn His 85 90 95 Pro Ile Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro Ala 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 312 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (H2) <400> 312 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asp Ile His Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 313 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (H11) <400> 313 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Ala Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Ile Tyr 35 40 45 Gly Arg Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asp Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Ala 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 314 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (H11) <400> 314 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ala Gly Ser Ser Ser Asp Tyr Trp Gly Arg Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 315 <211> 216 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (F12) <400> 315 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Ile Gly Asp Tyr 20 25 30 Asp Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Thr Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Arg Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Thr Ser Ser 85 90 95 Ser Val Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 316 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (F12) <400> 316 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Ser Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 317 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (B9) <400> 317 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr His Cys Gln Gln Ala Tyr Gly Phe Pro Leu 85 90 95 Thr Leu Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Ala Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Leu Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 318 <211> 452 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (B9) <400> 318 Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Glu Ile Ala Val Ala Gln Asn Trp Asp Tyr Tyr Gly Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr 115 120 125 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser 130 135 140 Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 145 150 155 160 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 165 170 175 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys 195 200 205 Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu 210 215 220 Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu 225 230 235 240 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr 290 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser 325 330 335 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445 Ser Leu Gly Lys 450 <210> 319 <211> 217 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (G11) <400> 319 Gln Ser Ala Leu Thr Gln Pro Arg Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ser Ser Ser 85 90 95 Ser Thr Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Ala Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 320 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Heavy chain (G11) <400> 320 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Ser Gln Tyr Tyr Asp Gly Gly Tyr Tyr Met Asp Val Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 321 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Light chain (G6) <400> 321 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Thr Ile Thr Cys Gln Gly Asp Ser Leu Arg Arg Tyr Tyr Ala 20 25 30 Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Gln Asn Tyr Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Thr Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Ala 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 322 <211> 446 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (G6) <400> 322 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Trp Gly Tyr Ser Ser Ser Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val 260 265 270 Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350 Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 323 <211> 216 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (F11) <400> 323 Gln Ser Val Leu Thr Gln Pro Pro Ser Thr Ser Gly Thr Pro Gly Gln 1 5 10 15 Thr Phe Ser Ile Phe Cys Ser Gly Ser Ser Ser Asn Ile Gly Thr Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Glu Thr Trp Asp Asp Ser Leu 85 90 95 Lys Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 324 <211> 446 <212> PRT <213> artificial sequence <220> <223> Link(F11) <400> 324 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Gly Ser Gly Asp Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Trp Glu Leu Gly Asp Ala Phe Asp Ile Trp Gly Arg Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val 260 265 270 Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350 Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 325 <211> 212 <212> PRT <213> Artificial Sequence <220> <223> chain link(D3) <400> 325 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Arg Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Ala Ala Ala 100 105 110 Pro Ser Val Thr Leu Phe Pro Ser Ser Glu Glu Leu Gln Ala Asn 115 120 125 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 130 135 140 Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu 145 150 155 160 Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser 165 170 175 Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser 180 185 190 Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro 195 200 205 Thr Glu Cys Ser 210 <210> 326 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (D3) <400> 326 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Arg Gly Ser Tyr Gly Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr 210 215 220 Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 260 265 270 Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 Lys <210> 327 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (B12) <400> 327 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Arg 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Ala Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Leu Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 328 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (B12) <400> 328 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ala Gly Ala Ser Ile Val Gly Ala Thr Ala Leu Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 195 200 205 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr 210 215 220 Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 260 265 270 Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 Lys <210> 329 <211> 218 <212> PRT <213> Artificial Sequence <220> <223> Light chain (E4) <400> 329 Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 1 5 10 15 Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn 20 25 30 Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val 35 40 45 Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 65 70 75 80 Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr 85 90 95 Gly Asn Arg Asn Tyr Val Phe Gly Thr Gly Thr Gln Leu Thr Val Leu 100 105 110 Gly Gln Pro Ala Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 115 120 125 Glu Glu Ile Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 130 135 140 Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 145 150 155 160 Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn 165 170 175 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 180 185 190 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 195 200 205 Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 330 <211> 448 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (E4) <400> 330 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Met Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Tyr Asp Asp Thr Ala Val Tyr Phe Cys 85 90 95 Val Arg Gly Pro Ser Leu Asn Tyr Ala Gly Tyr Phe Asp Asn Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 331 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (E12) <400> 331 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Glu Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Arg Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Gly Ser Thr Thr Asp Tyr 85 90 95 Met Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Gly Gln Pro Ala 100 105 110 Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 115 120 125 Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 130 135 140 Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 145 150 155 160 Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 165 170 175 Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 180 185 190 Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 195 200 205 Ala Pro Thr Glu Cys Ser 210 <210> 332 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (E12) <400> 332 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg Gly Ser Gly Met Asp Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 333 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Light chain (D1) <400> 333 Glu Thr Thr Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Thr Pro Gly 1 5 10 15 Asp Lys Val Asn Ile Ser Cys Lys Ala Ser Gln Asp Ile Asp Asp Asp 20 25 30 Met Asn Trp Tyr Gln Gln Lys Pro Gly Glu Ala Ala Ile Ser Ile Ile 35 40 45 Gln Glu Ala Ser Thr Leu Val Pro Gly Ile Pro Pro Arg Phe Ser Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser 65 70 75 80 Glu Asp Ala Ala Tyr Tyr Phe Cys Leu Gln His Asp Lys Phe Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Ala Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Leu Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 334 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (D1) <400> 334 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Arg Gly Val Asp Glu Gly Asp Tyr Trp Gly Gln Gly Thr Met 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 335 <211> 216 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (E6) <400> 335 Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 1 5 10 15 Thr Val Thr Leu Ser Cys Thr Gly Ser Ser Gly Asn Ile Ala Ser Asn 20 25 30 Tyr Val Gln Trp Tyr Gln His Arg Pro Gly Ser Ala Pro Thr Thr Val 35 40 45 Ile Tyr Arg Asp Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 65 70 75 80 Leu Arg Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser 85 90 95 Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 336 <211> 451 <212> PRT <213> Artificial Sequence <220> <223> Heavy chain (E6) <400> 336 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Asp Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Met Asn Pro Asn Ser Gly Asn Ser Arg Ser Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Ser Met Thr Ser Asp Ser Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Gly Asp Tyr Ser Gly Val Val Leu Thr Ala Thr Ala Leu Asp 100 105 110 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 115 120 125 Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu 130 135 140 Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 145 150 155 160 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 165 170 175 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 180 185 190 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn 195 200 205 Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser 210 215 220 Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln 260 265 270 Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Leu Gly Lys 450 <210> 337 <211> 216 <212> PRT <213> artificial sequence <220> <223> chain link(E9) <400> 337 Gln Ser Glu Leu Thr Gln Leu Pro Ser Ala Ser Glu Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Ala Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 338 <211> 450 <212> PRT <213> Artificial Sequence <220> <223> Heavy Chain (E9) <400> 338 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Asp Arg Ile Ala Ala Ala Gly Met Arg Glu Leu Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val 195 200 205 Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys 210 215 220 Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu 260 265 270 Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu 435 440 445 Gly Lys 450 <210> 339 <211> 220 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (A11) <400> 339 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys Arg Thr Ala Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Leu Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 <210> 340 <211> 447 <212> PRT <213> Artificial sequence <220> <223> Heavy chain (A11) <400> 340 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Glu Gln Pro Gly Gly 1 5 10 15 Phe Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Thr Ser Tyr 20 25 30 Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Ser Asp Gly Thr Thr Thr Thr Tyr Ala Asp Ser Val 50 55 60 Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gln Leu Leu Gly Trp Asp Ala Leu Asn Val Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 341 <211> 327 <212> PRT <213> Artificial sequence <220> <223> IgG4 Fc <400> 341 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310 315 320 Leu Ser Leu Ser Leu Gly Lys 325 <210> 342 <211> 102 <212> PRT <213> Artificial sequence <220> <223> κ constant region <400> 342 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 1 5 10 15 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 20 25 30 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 35 40 45 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 50 55 60 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Leu Tyr 65 70 75 80 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 85 90 95 Phe Asn Arg Gly Glu Cys 100 <210> 343 <211> 100 <212> PRT <213> Artificial sequence <220> <223> λ constant region <400> 343 Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn 1 5 10 15 Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 20 25 30 Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu 35 40 45 Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser 50 55 60 Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser 65 70 75 80 Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro 85 90 95 Thr Glu Cys Ser 100 <210> 344 <211> 106 <212> PRT <213> Artificial sequence <220> <223> λ CL.1 constant region <400> 344 Gly Gln Pro Lys Ala Asn Pro Thr Val Thr Leu Phe Pro Pro Ser Ser 1 5 10 15 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 20 25 30 Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro 35 40 45 Val Lys Ala Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn 50 55 60 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 65 70 75 80 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 85 90 95 Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 100 105 <210> 345 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> Light chain variable region (E3.1) <400> 345 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Asn Phe Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Met Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Ser His 85 90 95 Leu Thr Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 346 <211> 330 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region (E3.1) encoding gene <400> 346 Thr Cys Cys Thr Ala Thr Gly Ala Gly Cys Thr Gly Ala Cys Thr Cys 1 5 10 15 Ala Gly Gly Ala Cys Cys Cys Thr Gly Cys Thr Gly Thr Gly Thr Cys 20 25 30 Thr Gly Thr Gly Gly Cys Cys Thr Thr Gly Gly Gly Ala Cys Ala Gly 35 40 45 Ala Cys Ala Gly Thr Cys Ala Gly Gly Ala Thr Cys Ala Cys Ala Thr 50 55 60 Gly Cys Cys Ala Gly Gly Gly Ala Gly Ala Cys Ala Gly Cys Cys Thr 65 70 75 80 Cys Ala Gly Ala Ala Ala Cys Thr Thr Thr Thr Ala Thr Gly Cys Ala 85 90 95 Ala Gly Cys Thr Gly Gly Thr Ala Cys Cys Ala Gly Cys Ala Gly Ala 100 105 110 Ala Gly Thr Cys Ala Gly Gly Ala Cys Ala Gly Gly Cys Cys Cys Cys 115 120 125 Ala Gly Thr Thr Cys Thr Thr Gly Thr Cys Ala Thr Gly Thr Ala Thr 130 135 140 Gly Gly Thr Ala Ala Ala Ala Ala Cys Ala Ala Cys Cys Gly Gly Cys 145 150 155 160 Cys Cys Thr Cys Ala Gly Gly Gly Ala Thr Cys Cys Cys Ala Gly Ala 165 170 175 Cys Cys Gly Ala Thr Thr Cys Thr Cys Thr Gly Gly Cys Thr Cys Cys 180 185 190 Ala Cys Cys Thr Cys Ala Gly Gly Ala Ala Ala Cys Ala Cys Ala Gly 195 200 205 Cys Thr Thr Cys Cys Thr Thr Gly Ala Cys Cys Ala Thr Cys Ala Cys 210 215 220 Thr Gly Gly Gly Gly Cys Thr Cys Ala Gly Gly Cys Gly Gly Ala Ala 225 230 235 240 Gly Ala Thr Gly Ala Gly Gly Cys Thr Gly Ala Cys Thr Ala Thr Thr 245 250 255 Ala Cys Thr Gly Thr Ala Ala Cys Thr Cys Cys Cys Gly Gly Gly Ala 260 265 270 Cys Ala Gly Cys Ala Gly Thr Gly Gly Thr Ala Gly Cys Cys Ala Thr 275 280 285 Thr Thr Gly Ala Cys Gly Gly Gly Cys Gly Thr Ala Thr Thr Cys Gly 290 295 300 Gly Cys Gly Gly Ala Gly Gly Gly Ala Cys Cys Ala Ala Gly Gly Thr 305 310 315 320 Cys Ala Cys Cys Gly Thr Cys Cys Thr Ala 325 330 <210> 347 <211> 216 <212> PRT <213> Artificial Sequence <220> <223> Light Chain (E3.1) <400> 347 Ser Tyr Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Asn Phe Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Met Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Ser His 85 90 95 Leu Thr Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Asn Pro Thr Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 348 <211> 650 <212> PRT <213> Artificial Sequence <220> <223> LILRB1(AAH15731) <400> 348 Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly His Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Arg 35 40 45 Cys Gln Gly Gly Gln Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu Lys 50 55 60 Lys Thr Ala Pro Trp Ile Thr Arg Ile Pro Gln Glu Leu Val Lys Lys 65 70 75 80 Gly Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Ala Gly Arg Tyr 85 90 95 Arg Cys Tyr Tyr Gly Ser Asp Thr Ala Gly Arg Ser Glu Ser Ser Asp 100 105 110 Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu Ser 115 120 125 Ala Gln Pro Ser Pro Val Val Asn Ser Gly Gly Asn Val Thr Leu Gln 130 135 140 Cys Asp Ser Gln Val Ala Phe Asp Gly Phe Ile Leu Cys Lys Glu Gly 145 150 155 160 Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro His Ala Arg Gly 165 170 175 Ser Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg 180 185 190 Trp Trp Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro Tyr Glu Trp 195 200 205 Ser Leu Pro Ser Asp Leu Leu Glu Leu Leu Val Leu Gly Val Ser Lys 210 215 220 Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Ile Val Ala Pro Glu Glu 225 230 235 240 Thr Leu Thr Leu Gln Cys Gly Ser Asp Ala Gly Tyr Asn Arg Phe Val 245 250 255 Leu Tyr Lys Asp Gly Glu Arg Asp Phe Leu Gln Leu Ala Gly Ala Gln 260 265 270 Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser 275 280 285 Arg Ser Tyr Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser 290 295 300 Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly 305 310 315 320 Gln Phe Tyr Asp Arg Val Ser Leu Ser Val Gln Pro Gly Pro Thr Val 325 330 335 Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Gln Gly Trp Met 340 345 350 Gln Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala Asp Asp Pro Trp Arg 355 360 365 Leu Arg Ser Thr Tyr Gln Ser Gln Lys Tyr Gln Ala Glu Phe Pro Met 370 375 380 Gly Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser 385 390 395 400 Gln Ser Ser Lys Pro Tyr Leu Leu Thr His Pro Ser Asp Pro Leu Glu 405 410 415 Leu Val Val Ser Gly Pro Ser Gly Gly Pro Ser Ser Pro Thr Thr Gly 420 425 430 Pro Thr Ser Thr Ser Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr Gly 435 440 445 Ser Asp Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Ile Gly 450 455 460 Ile Leu Val Ala Val Ile Leu Leu Leu Leu Leu Leu Leu Leu Leu Phe 465 470 475 480 Leu Ile Leu Arg His Arg Arg Gln Gly Lys His Trp Thr Ser Thr Gln 485 490 495 Arg Lys Ala Asp Phe Gln His Pro Ala Gly Ala Val Gly Pro Glu Pro 500 505 510 Thr Asp Arg Gly Leu Gln Trp Arg Ser Ser Pro Ala Ala Asp Ala Gln 515 520 525 Glu Glu Asn Leu Tyr Ala Ala Val Lys His Thr Gln Pro Glu Asp Gly 530 535 540 Val Glu Met Asp Thr Arg Ser Pro His Asp Glu Asp Pro Gln Ala Val 545 550 555 560 Thr Tyr Ala Glu Val Lys His Ser Arg Pro Arg Arg Glu Met Ala Ser 565 570 575 Pro Pro Ser Pro Leu Ser Gly Glu Phe Leu Asp Thr Lys Asp Arg Gln 580 585 590 Ala Glu Glu Asp Arg Gln Met Asp Thr Glu Ala Ala Ala Ser Glu Ala 595 600 605 Pro Gln Asp Val Thr Tyr Ala Gln Leu His Ser Leu Thr Leu Arg Arg 610 615 620 Lys Ala Thr Glu Pro Pro Pro Ser Gln Glu Gly Pro Ser Pro Ala Val 625 630 635 640 Pro Ser Ile Tyr Ala Thr Leu Ala Ile His 645 650 <210> 349 <211> 598 <212> PRT <213> Artificial Sequence <220> <223> LILRB2(AAH36827) <400> 349 Met Thr Pro Ile Val Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Thr Gly Thr Ile Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Asp Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Ser 35 40 45 Cys Gln Gly Ser Leu Glu Ala Gln Glu Tyr Arg Leu Tyr Arg Glu Lys 50 55 60 Lys Ser Ala Ser Trp Ile Thr Arg Ile Arg Pro Glu Leu Val Lys Asn 65 70 75 80 Gly Gln Phe His Ile Pro Ser Ile Thr Trp Glu His Thr Gly Arg Tyr 85 90 95 Gly Cys Gln Tyr Tyr Ser Arg Ala Arg Trp Ser Glu Leu Ser Asp Pro 100 105 110 Leu Val Leu Val Met Thr Gly Ala Tyr Pro Lys Pro Thr Leu Ser Ala 115 120 125 Gln Pro Ser Pro Val Val Thr Ser Gly Gly Arg Val Thr Leu Gln Cys 130 135 140 Glu Ser Gln Val Ala Phe Gly Gly Phe Ile Leu Cys Lys Glu Gly Glu 145 150 155 160 Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro His Ala Arg Gly Ser 165 170 175 Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Asn Arg Arg Trp 180 185 190 Ser His Arg Cys Tyr Gly Tyr Asp Leu Asn Ser Pro Tyr Val Trp Ser 195 200 205 Ser Pro Ser Asp Leu Leu Glu Leu Leu Val Pro Gly Val Ser Lys Lys 210 215 220 Pro Ser Leu Ser Val Gln Pro Gly Pro Val Val Ala Pro Gly Glu Ser 225 230 235 240 Leu Thr Leu Gln Cys Val Ser Asp Val Gly Tyr Asp Arg Phe Val Leu 245 250 255 Tyr Lys Glu Gly Glu Arg Asp Leu Arg Gln Leu Pro Gly Arg Gln Pro 260 265 270 Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Arg 275 280 285 Ser Tyr Gly Gly Gln Tyr Arg Cys Tyr Gly Ala Tyr Asn Leu Ser Ser 290 295 300 Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Thr Gly Gln 305 310 315 320 Ile His Gly Thr Pro Phe Ile Ser Val Gln Pro Gly Pro Thr Val Ala 325 330 335 Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp Arg Gln Phe His 340 345 350 Thr Phe Leu Leu Thr Lys Ala Gly Ala Ala Asp Ala Pro Leu Arg Leu 355 360 365 Arg Ser Ile His Glu Tyr Pro Lys Tyr Gln Ala Glu Phe Pro Met Ser 370 375 380 Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser Leu 385 390 395 400 Asn Ser Asp Pro Tyr Leu Leu Ser His Pro Ser Glu Pro Leu Glu Leu 405 410 415 Val Val Ser Gly Pro Ser Met Gly Ser Ser Pro Pro Pro Thr Gly Pro 420 425 430 Ile Ser Thr Pro Ala Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr Gly 435 440 445 Ser Asp Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Ile Gly 450 455 460 Ile Leu Val Ala Val Val Leu Leu Leu Leu Leu Leu Leu Leu Leu Phe 465 470 475 480 Leu Ile Leu Arg His Arg Arg Gln Gly Lys His Trp Thr Ser Thr Gln 485 490 495 Arg Lys Ala Asp Phe Gln His Pro Ala Gly Ala Val Gly Pro Glu Pro 500 505 510 Thr Asp Arg Gly Leu Gln Trp Arg Ser Ser Pro Ala Ala Asp Ala Gln 515 520 525 Glu Glu Asn Leu Tyr Ala Ala Val Lys Asp Thr Gln Pro Glu Asp Gly 530 535 540 Val Glu Met Asp Thr Arg Ala Ala Ala Ser Glu Ala Pro Gln Asp Val 545 550 555 560 Thr Tyr Ala Gln Leu His Ser Leu Thr Leu Arg Arg Lys Ala Thr Glu 565 570 575 Pro Pro Pro Ser Gln Glu Gly Glu Pro Pro Ala Glu Pro Ser Ile Tyr 580 585 590 Ala Thr Leu Ala Ile His 595 <210> 350 <211> 631 <212> PRT <213> artificial sequence <220> <223> LILRB3(XP_006726377) <400> 350 Met Thr Pro Ala Leu Thr Ala Leu Leu Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr Arg Val Gln Ala Gly Pro Phe Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Ser Trp Gly Ser Pro Val Thr Ile Trp 35 40 45 Cys Gln Gly Ser Leu Glu Ala Gln Glu Tyr Arg Leu Asp Lys Glu Gly 50 55 60 Ser Pro Glu Pro Leu Asp Arg Asn Asn Pro Leu Glu Pro Lys Asn Lys 65 70 75 80 Ala Arg Phe Ser Ile Pro Ser Met Thr Glu His His Ala Gly Arg Tyr 85 90 95 Arg Cys His Tyr Tyr Ser Ser Ala Gly Trp Ser Glu Pro Ser Asp Pro 100 105 110 Leu Glu Leu Val Met Thr Gly Phe Tyr Asn Lys Pro Thr Leu Ser Ala 115 120 125 Leu Pro Ser Pro Val Val Ala Ser Gly Gly Asn Met Thr Leu Arg Cys 130 135 140 Gly Ser Gln Lys Gly Tyr His His Phe Val Leu Met Lys Glu Gly Glu 145 150 155 160 His Gln Leu Pro Arg Thr Leu Asp Ser Gln Gln Leu His Ser Gly Gly 165 170 175 Phe Gln Ala Leu Phe Pro Val Gly Pro Val Asn Pro Ser His Arg Trp 180 185 190 Arg Phe Thr Cys Tyr Tyr Tyr Tyr Met Asn Thr Pro Gln Val Trp Ser 195 200 205 His Pro Ser Asp Pro Leu Glu Ile Leu Pro Ser Gly Val Ser Arg Lys 210 215 220 Pro Ser Leu Leu Thr Leu Gln Gly Pro Val Leu Ala Pro Gly Gln Ser 225 230 235 240 Leu Thr Leu Gln Cys Gly Ser Asp Val Gly Tyr Asp Arg Phe Val Leu 245 250 255 Tyr Lys Glu Gly Glu Arg Asp Phe Leu Gln Arg Pro Gly Gln Gln Pro 260 265 270 Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Pro 275 280 285 Ser His Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser Ser 290 295 300 Glu Trp Ser Ala Pro Ser Asp Pro Leu Asn Ile Leu Met Ala Gly Gln 305 310 315 320 Ile Tyr Asp Thr Val Ser Leu Ser Ala Gln Pro Gly Pro Thr Val Ala 325 330 335 Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp Trp Gln Phe Asp 340 345 350 Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala His Pro Pro Leu Arg Leu 355 360 365 Arg Ser Met Tyr Gly Ala His Lys Tyr Gln Ala Glu Phe Pro Met Ser 370 375 380 Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser Tyr 385 390 395 400 Ser Ser Asn Pro His Leu Leu Ser Phe Pro Ser Glu Pro Leu Glu Leu 405 410 415 Met Val Ser Gly His Ser Gly Gly Ser Ser Leu Pro Pro Thr Gly Pro 420 425 430 Pro Ser Thr Pro Gly Leu Gly Arg Tyr Leu Glu Val Leu Ile Gly Val 435 440 445 Ser Val Ala Phe Val Leu Leu Leu Phe Leu Leu Leu Phe Leu Leu Leu 450 455 460 Arg Arg Gln Arg His Ser Lys His Arg Thr Ser Asp Gln Arg Lys Thr 465 470 475 480 Asp Phe Gln Arg Pro Ala Gly Ala Ala Glu Thr Glu Pro Lys Asp Arg 485 490 495 Gly Leu Leu Arg Arg Ser Ser Pro Ala Ala Asp Val Gln Glu Glu Asn 500 505 510 Leu Tyr Ala Ala Val Lys Asp Thr Gln Ser Glu Asp Arg Val Glu Leu 515 520 525 Asp Ser Gln Ser Pro His Asp Glu Asp Pro Gln Ala Val Thr Tyr Ala 530 535 540 Pro Val Lys His Ser Ser Pro Arg Arg Glu Met Ala Ser Pro Pro Ser 545 550 555 560 Ser Leu Ser Gly Glu Phe Leu Asp Thr Lys Asp Arg Gln Val Glu Glu 565 570 575 Asp Arg Gln Met Asp Thr Glu Ala Ala Ala Ser Glu Ala Ser Gln Asp 580 585 590 Val Thr Tyr Ala Gln Leu His Ser Leu Thr Leu Arg Arg Lys Ala Thr 595 600 605 Glu Pro Pro Pro Ser Gln Glu Gly Glu Pro Pro Ala Glu Pro Ser Ile 610 615 620 Tyr Ala Thr Leu Ala Ile His 625 630 <210> 351 <211> 448 <212> PRT <213> Synthetic Sequence <220> <223> LILRB4(NP_001265355) <400> 351 Met Ile Pro Thr Phe Thr Ala Leu Leu Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Met Gln Ala Gly Pro Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Ser Trp Gly Asn Ser Val Thr Ile Trp 35 40 45 Cys Gln Gly Thr Leu Glu Ala Arg Glu Tyr Arg Leu Asp Lys Glu Glu 50 55 60 Ser Pro Ala Pro Trp Asp Arg Gln Asn Pro Leu Glu Pro Lys Asn Lys 65 70 75 80 Ala Arg Phe Ser Ile Pro Ser Met Thr Glu Asp Tyr Ala Gly Arg Tyr 85 90 95 Arg Cys Tyr Tyr Arg Ser Pro Val Gly Trp Ser Gln Pro Ser Asp Pro 100 105 110 Leu Glu Leu Val Met Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala 115 120 125 Leu Pro Ser Pro Leu Val Thr Ser Gly Lys Ser Val Thr Leu Leu Cys 130 135 140 Gln Ser Arg Ser Pro Met Asp Thr Phe Leu Leu Ile Lys Glu Arg Ala 145 150 155 160 Ala His Pro Leu Leu His Leu Arg Ser Glu His Gly Ala Gln Gln His 165 170 175 Gln Ala Glu Phe Pro Met Ser Pro Val Thr Ser Val His Gly Gly Thr 180 185 190 Tyr Arg Cys Phe Ser Ser His Gly Phe Ser His Tyr Leu Leu Ser His 195 200 205 Pro Ser Asp Pro Leu Glu Leu Ile Val Ser Gly Ser Leu Glu Gly Pro 210 215 220 Arg Pro Ser Pro Thr Arg Ser Val Ser Thr Ala Ala Gly Pro Glu Asp 225 230 235 240 Gln Pro Leu Met Pro Thr Gly Ser Val Pro His Ser Gly Leu Arg Arg 245 250 255 His Trp Glu Val Leu Ile Gly Val Leu Val Val Ser Ile Leu Leu Leu 260 265 270 Ser Leu Leu Leu Phe Leu Leu Leu Gln His Trp Arg Gln Gly Lys His 275 280 285 Arg Thr Leu Ala Gln Arg Gln Ala Asp Phe Gln Arg Pro Pro Gly Ala 290 295 300 Ala Glu Pro Glu Pro Lys Asp Gly Gly Leu Gln Arg Arg Ser Ser Pro 305 310 315 320 Ala Ala Asp Val Gln Gly Glu Asn Phe Cys Ala Ala Val Lys Asn Thr 325 330 335 Gln Pro Glu Asp Gly Val Glu Met Asp Thr Arg Gln Ser Pro His Asp 340 345 350 Glu Asp Pro Gln Ala Val Thr Tyr Ala Lys Val Lys His Ser Arg Pro 355 360 365 Arg Arg Glu Met Ala Ser Pro Pro Ser Pro Leu Ser Gly Glu Phe Leu 370 375 380 Asp Thr Lys Asp Arg Gln Ala Glu Glu Asp Arg Gln Met Asp Thr Glu 385 390 395 400 Ala Ala Ala Ser Glu Ala Pro Gln Asp Val Thr Tyr Ala Arg Leu His 405 410 415 Ser Phe Thr Leu Arg Gln Lys Ala Thr Glu Pro Pro Pro Ser Gln Glu 420 425 430 Gly Ala Ser Pro Ala Glu Pro Ser Val Tyr Ala Thr Leu Ala Ile His 435 440 445 <210> 352 <211> 590 <212> PRT <213> Artificial Sequence <220> <223> LILRB5(NP_006831) <400> 352 Met Thr Leu Thr Leu Ser Val Leu Ile Cys Leu Gly Leu Ser Val Gly 1 5 10 15 Pro Arg Thr Cys Val Gln Ala Gly Thr Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Ala Ser Val Ile Ala Arg Gly Lys Pro Val Thr Leu Trp 35 40 45 Cys Gln Gly Pro Leu Glu Thr Glu Glu Tyr Arg Leu Asp Lys Glu Gly 50 55 60 Leu Pro Trp Ala Arg Lys Arg Gln Asn Pro Leu Glu Pro Gly Ala Lys 65 70 75 80 Ala Lys Phe His Ile Pro Ser Thr Val Tyr Asp Ser Ala Gly Arg Tyr 85 90 95 Arg Cys Tyr Tyr Glu Thr Pro Ala Gly Trp Ser Glu Pro Ser Asp Pro 100 105 110 Leu Glu Leu Val Ala Thr Gly Phe Tyr Ala Glu Pro Thr Leu Leu Ala 115 120 125 Leu Pro Ser Pro Val Val Ala Ser Gly Gly Asn Val Thr Leu Gln Cys 130 135 140 Asp Thr Leu Asp Gly Leu Leu Thr Phe Val Leu Val Glu Glu Glu Gln 145 150 155 160 Lys Leu Pro Arg Thr Leu Tyr Ser Gln Lys Leu Pro Lys Gly Pro Ser 165 170 175 Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro Ser Cys Arg Trp Arg 180 185 190 Phe Arg Cys Tyr Tyr Tyr Tyr Arg Lys Asn Pro Gln Val Trp Ser Asn 195 200 205 Pro Ser Asp Leu Leu Glu Ile Leu Val Pro Gly Val Ser Arg Lys Pro 210 215 220 Ser Leu Leu Ile Pro Gln Gly Ser Val Val Ala Arg Gly Gly Ser Leu 225 230 235 240 Thr Leu Gln Cys Arg Ser Asp Val Gly Tyr Asp Ile Phe Val Leu Tyr 245 250 255 Lys Glu Gly Glu His Asp Leu Val Gln Gly Ser Gly Gln Gln Pro Gln 260 265 270 Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Arg Ser 275 280 285 His Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser Pro Arg 290 295 300 Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly Leu Ile 305 310 315 320 Pro Asp Ile Pro Ala Leu Ser Val Gln Pro Gly Pro Lys Val Ala Ser 325 330 335 Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp His Gln Ile Asp Thr 340 345 350 Phe Phe Leu Thr Lys Glu Gly Ala Ala His Pro Pro Leu Cys Leu Lys 355 360 365 Ser Lys Tyr Gln Ser Tyr Arg His Gln Ala Glu Phe Ser Met Ser Pro 370 375 380 Val Thr Ser Ala Gln Gly Gly Thr Tyr Arg Cys Tyr Ser Ala Ile Arg 385 390 395 400 Ser Tyr Pro Tyr Leu Leu Ser Ser Pro Ser Tyr Pro Gln Glu Leu Val 405 410 415 Val Ser Gly Pro Ser Gly Asp Pro Ser Leu Ser Pro Thr Gly Ser Thr 420 425 430 Pro Thr Pro Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr Gly Leu Asp 435 440 445 Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Thr Gly Val Ser 450 455 460 Val Ala Phe Val Leu Leu Leu Phe Leu Leu Leu Phe Leu Leu Leu Arg 465 470 475 480 His Arg His Gln Ser Lys His Arg Thr Ser Ala His Phe Tyr Arg Pro 485 490 495 Ala Gly Ala Ala Gly Pro Glu Pro Lys Asp Gln Gly Leu Gln Lys Arg 500 505 510 Ala Ser Pro Val Ala Asp Ile Gln Glu Glu Ile Leu Asn Ala Ala Val 515 520 525 Lys Asp Thr Gln Pro Lys Asp Gly Val Glu Met Asp Ala Arg Ala Ala 530 535 540 Ala Ser Glu Ala Pro Gln Asp Val Thr Tyr Ala Gln Leu His Ser Leu 545 550 555 560 Thr Leu Arg Arg Glu Ala Thr Glu Pro Pro Pro Ser Gln Glu Arg Glu 565 570 575 Pro Pro Ala Glu Pro Ser Ile Tyr Ala Pro Leu Ala Ile His 580 585 590 <210> 353 <211> 489 <212> PRT <213> artificial sequence <220> <223> LILRA1(NP_006854) <400> 353 Met Thr Pro Ile Val Thr Val Leu Ile Cys Leu Arg Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly Thr Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Trp 35 40 45 Cys Gln Gly Ile Leu Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu Lys 50 55 60 Lys Thr Ala Pro Trp Ile Thr Arg Ile Pro Gln Glu Ile Val Lys Lys 65 70 75 80 Gly Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Thr Gly Arg Tyr 85 90 95 Arg Cys Phe Tyr Gly Ser His Thr Ala Gly Trp Ser Glu Pro Ser Asp 100 105 110 Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu Ser 115 120 125 Ala Leu Pro Ser Pro Val Val Thr Ser Gly Gly Asn Val Thr Leu His 130 135 140 Cys Val Ser Gln Val Ala Phe Gly Ser Phe Ile Leu Cys Lys Glu Gly 145 150 155 160 Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro Arg Thr His Gly 165 170 175 Trp Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg 180 185 190 Trp Ser Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro His Val Trp 195 200 205 Ser Leu Pro Ser Asp Leu Leu Glu Leu Leu Val Leu Gly Val Ser Lys 210 215 220 Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Ile Val Ala Pro Gly Glu 225 230 235 240 Ser Leu Thr Leu Gln Cys Val Ser Asp Val Ser Tyr Asp Arg Phe Val 245 250 255 Leu Tyr Lys Glu Gly Glu Arg Asp Phe Leu Gln Leu Pro Gly Pro Gln 260 265 270 Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser 275 280 285 Arg Ser Tyr Gly Gly Gln Tyr Arg Cys Ser Gly Ala Tyr Asn Leu Ser 290 295 300 Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly 305 310 315 320 Gln Phe Arg Gly Arg Pro Phe Ile Ser Val His Pro Gly Pro Thr Val 325 330 335 Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp Gly Pro Phe 340 345 350 His Thr Phe Leu Leu Thr Lys Ala Gly Ala Ala Asp Ala Pro Leu Arg 355 360 365 Leu Arg Ser Ile His Glu Tyr Pro Lys Tyr Gln Ala Glu Phe Pro Met 370 375 380 Ser Pro Val Thr Ser Ala His Ser Gly Thr Tyr Arg Cys Tyr Gly Ser 385 390 395 400 Leu Ser Ser Asn Pro Tyr Leu Leu Ser His Pro Ser Asp Ser Leu Glu 405 410 415 Leu Met Val Ser Gly Ala Ala Glu Thr Leu Ser Pro Pro Gln Asn Lys 420 425 430 Ser Asp Ser Lys Ala Gly Ala Ala Asn Thr Leu Ser Pro Ser Gln Asn 435 440 445 Lys Thr Ala Ser His Pro Gln Asp Tyr Thr Val Glu Asn Leu Ile Arg 450 455 460 Met Gly Ile Ala Gly Leu Val Leu Val Val Leu Gly Ile Leu Leu Phe 465 470 475 480 Glu Ala Gln His Ser Gln Arg Ser Leu 485 <210> 354 <211> 466 <212> PRT <213> Artificial sequence <220> <223> LILRA2(AAH17412) <400> 354 Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly His Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Ile Gln Gly Ser Pro Val Thr Leu Arg 35 40 45 Cys Gln Gly Ser Leu Gln Ala Glu Glu Tyr His Leu Tyr Arg Glu Asn 50 55 60 Lys Ser Ala Ser Trp Val Arg Arg Ile Gln Glu Pro Gly Lys Asn Gly 65 70 75 80 Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Ala Gly Arg Tyr His 85 90 95 Cys Gln Tyr Tyr Ser His Asn His Ser Ser Glu Tyr Ser Asp Pro Leu 100 105 110 Glu Leu Val Val Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala Leu 115 120 125 Pro Ser Pro Val Val Thr Leu Gly Gly Asn Val Thr Leu Gln Cys Val 130 135 140 Ser Gln Val Ala Phe Asp Gly Phe Ile Leu Cys Lys Glu Gly Glu Asp 145 150 155 160 Glu His Pro Gln Arg Leu Asn Ser His Ser His Ala Arg Gly Trp Ser 165 170 175 Trp Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg Trp Ser 180 185 190 Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro Tyr Val Trp Ser Leu 195 200 205 Pro Ser Asp Leu Leu Glu Leu Leu Val Pro Gly Val Ser Lys Lys Pro 210 215 220 Ser Leu Ser Val Gln Pro Gly Pro Met Val Ala Pro Gly Glu Ser Leu 225 230 235 240 Thr Leu Gln Cys Val Ser Asp Val Gly Tyr Asp Arg Phe Val Leu Tyr 245 250 255 Lys Glu Gly Glu Arg Asp Phe Leu Gln Arg Pro Gly Trp Gln Pro Gln 260 265 270 Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Pro Ser 275 280 285 His Gly Gly Gln Tyr Arg Cys Tyr Ser Ala His Asn Leu Ser Ser Glu 290 295 300 Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Thr Gly Gln Phe 305 310 315 320 Tyr Asp Arg Pro Ser Leu Ser Val Gln Pro Val Pro Thr Val Ala Pro 325 330 335 Gly Lys Asn Val Thr Leu Leu Cys Gln Ser Arg Gly Gln Phe His Thr 340 345 350 Phe Leu Leu Thr Lys Glu Gly Ala Gly His Pro Pro Leu His Leu Arg 355 360 365 Ser Glu His Gln Ala Gln Gln Asn Gln Ala Glu Phe Arg Met Gly Pro 370 375 380 Val Thr Ser Ala His Val Gly Thr Tyr Arg Cys Tyr Ser Ser Leu Ser 385 390 395 400 Ser Asn Pro Tyr Leu Leu Ser Leu Pro Ser Asp Pro Leu Glu Leu Val 405 410 415 Val Ser Ala Ser Leu Gly Gln His Pro Gln Asp Tyr Thr Val Glu Asn 420 425 430 Leu Ile Arg Met Gly Val Ala Gly Leu Val Leu Val Val Leu Gly Ile 435 440 445 Leu Leu Phe Glu Ala Gln His Ser Gln Arg Ser Leu Gln Asp Ala Ala 450 455 460 Gly Arg 465 <210> 355 <211> 439 <212> PRT <213> Artificial Sequence <220> <223> LILRA3(AAH28208) <400> 355 Met Thr Ser Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Asp 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly Pro Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Arg 35 40 45 Cys Gln Gly Ser Leu Glu Thr Gln Glu Tyr His Leu Tyr Arg Glu Lys 50 55 60 Lys Thr Ala Leu Trp Ile Thr Arg Ile Pro Gln Glu Leu Val Lys Lys 65 70 75 80 Gly Gln Phe Pro Ile Leu Ser Ile Thr Trp Glu His Ala Gly Arg Tyr 85 90 95 Cys Cys Ile Tyr Gly Ser His Thr Val Gly Leu Ser Glu Ser Ser Asp 100 105 110 Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser 115 120 125 Ala Leu Pro Ser Pro Val Val Thr Ser Gly Gly Asn Val Thr Ile Gln 130 135 140 Cys Asp Ser Gln Val Ala Phe Asp Gly Phe Ile Leu Cys Lys Glu Gly 145 150 155 160 Glu Asp Glu His Pro Gln Cys Leu Asn Ser His Ser His Ala Arg Gly 165 170 175 Ser Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg 180 185 190 Trp Ser Tyr Arg Cys Tyr Gly Tyr Asp Ser Arg Ala Pro Tyr Val Trp 195 200 205 Ser Leu Pro Ser Asp Leu Leu Gly Leu Leu Val Pro Gly Val Ser Lys 210 215 220 Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Val Val Ala Pro Gly Glu 225 230 235 240 Lys Leu Thr Phe Gln Cys Gly Ser Asp Ala Gly Tyr Asp Arg Phe Val 245 250 255 Leu Tyr Lys Glu Trp Gly Arg Asp Phe Leu Gln Arg Pro Gly Arg Gln 260 265 270 Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser 275 280 285 Arg Ser Tyr Gly Gly Gln Tyr Thr Cys Ser Gly Ala Tyr Asn Leu Ser 290 295 300 Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Thr Gly 305 310 315 320 Gln Ile Arg Ala Arg Pro Phe Leu Ser Val Arg Pro Gly Pro Thr Val 325 330 335 Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Gln Gly Gly Met 340 345 350 His Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala Asp Ser Pro Leu Arg 355 360 365 Leu Lys Ser Lys Arg Gln Ser His Lys Tyr Gln Ala Glu Phe Pro Met 370 375 380 Ser Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser 385 390 395 400 Leu Ser Ser Asn Pro Tyr Leu Leu Thr His Pro Ser Asp Pro Leu Glu 405 410 415 Leu Val Val Ser Gly Ala Ala Glu Thr Leu Ser Pro Pro Gln Asn Lys 420 425 430 Ser Asp Ser Lys Ala Gly Glu 435 <210> 356 <211> 499 <212> PRT <213> Artificial sequence <220> <223> LILRA4(NP_036408) <400> 356 Met Thr Leu Ile Leu Thr Ser Leu Leu Phe Phe Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr Arg Val Gln Ala Glu Asn Leu Pro Lys Pro Ile Leu Trp 20 25 30 Ala Glu Pro Gly Pro Val Ile Thr Trp His Asn Pro Val Thr Ile Trp 35 40 45 Cys Gln Gly Thr Leu Glu Ala Gln Gly Tyr Arg Leu Asp Lys Glu Gly 50 55 60 Asn Ser Met Ser Arg His Ile Leu Lys Thr Leu Glu Ser Glu Asn Lys 65 70 75 80 Val Lys Leu Ser Ile Pro Ser Met Met Trp Glu His Ala Gly Arg Tyr 85 90 95 His Cys Tyr Tyr Gln Ser Pro Ala Gly Trp Ser Glu Pro Ser Asp Pro 100 105 110 Leu Glu Leu Val Val Thr Ala Tyr Ser Arg Pro Thr Leu Ser Ala Leu 115 120 125 Pro Ser Pro Val Val Thr Ser Gly Val Asn Val Thr Leu Arg Cys Ala 130 135 140 Ser Arg Leu Gly Leu Gly Arg Phe Thr Leu Ile Glu Glu Gly Asp His 145 150 155 160 Arg Leu Ser Trp Thr Leu Asn Ser His Gln His Asn His Gly Lys Phe 165 170 175 Gln Ala Leu Phe Pro Met Gly Pro Leu Thr Phe Ser Asn Arg Gly Thr 180 185 190 Phe Arg Cys Tyr Gly Tyr Glu Asn Asn Thr Pro Tyr Val Trp Ser Glu 195 200 205 Pro Ser Asp Pro Leu Gln Leu Leu Val Ser Gly Val Ser Arg Lys Pro 210 215 220 Ser Leu Leu Thr Leu Gln Gly Pro Val Val Thr Pro Gly Glu Asn Leu 225 230 235 240 Thr Leu Gln Cys Gly Ser Asp Val Gly Tyr Ile Arg Tyr Thr Leu Tyr 245 250 255 Lys Glu Gly Ala Asp Gly Leu Pro Gln Arg Pro Gly Arg Gln Pro Gln 260 265 270 Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Ser Pro Val Ser Arg Ser 275 280 285 Tyr Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Val Ser Ser Glu 290 295 300 Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly Gln Ile 305 310 315 320 Ser Asp Arg Pro Ser Leu Ser Val Gln Pro Gly Pro Thr Val Thr Ser 325 330 335 Gly Glu Lys Val Thr Leu Leu Cys Gln Ser Trp Asp Pro Met Phe Thr 340 345 350 Phe Leu Leu Thr Lys Glu Gly Ala Ala His Pro Pro Leu Arg Leu Arg 355 360 365 Ser Met Tyr Gly Ala His Lys Tyr Gln Ala Glu Phe Pro Met Ser Pro 370 375 380 Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser Arg Ser 385 390 395 400 Ser Asn Pro Tyr Leu Leu Ser His Pro Ser Glu Pro Leu Glu Leu Val 405 410 415 Val Ser Gly Ala Thr Glu Thr Leu Asn Pro Ala Gln Lys Lys Ser Asp 420 425 430 Ser Lys Thr Ala Pro His Leu Gln Asp Tyr Thr Val Glu Asn Leu Ile 435 440 445 Arg Met Gly Val Ala Gly Leu Val Leu Leu Phe Leu Gly Ile Leu Leu 450 455 460 Phe Glu Ala Gln His Ser Gln Arg Ser Pro Pro Arg Cys Ser Gln Glu 465 470 475 480 Ala Asn Ser Arg Lys Asp Asn Ala Pro Phe Arg Val Val Glu Pro Trp 485 490 495 Glu Gln Ile <210> 357 <211> 299 <212> PRT <213> artificial sequence <220> <223> LILRA5(NP_067073) <400> 357 Met Ala Pro Trp Ser His Pro Ser Ala Gln Leu Gln Pro Val Gly Gly 1 5 10 15 Asp Ala Val Ser Pro Ala Leu Met Val Leu Leu Cys Leu Gly Leu Ser 20 25 30 Leu Gly Pro Arg Thr His Val Gln Ala Gly Asn Leu Ser Lys Ala Thr 35 40 45 Leu Trp Ala Glu Pro Gly Ser Val Ile Ser Arg Gly Asn Ser Val Thr 50 55 60 Ile Arg Cys Gln Gly Thr Leu Glu Ala Gln Glu Tyr Arg Leu Val Lys 65 70 75 80 Glu Gly Ser Pro Glu Pro Trp Asp Thr Gln Asn Pro Leu Glu Pro Lys 85 90 95 Asn Lys Ala Arg Phe Ser Ile Pro Ser Met Thr Glu His His Ala Gly 100 105 110 Arg Tyr Arg Cys Tyr Tyr Tyr Ser Pro Ala Gly Trp Ser Glu Pro Ser 115 120 125 Asp Pro Leu Glu Leu Val Val Thr Gly Phe Tyr Asn Lys Pro Thr Leu 130 135 140 Ser Ala Leu Pro Ser Pro Val Val Thr Ser Gly Glu Asn Val Thr Leu 145 150 155 160 Gln Cys Gly Ser Arg Leu Arg Phe Asp Arg Phe Ile Leu Thr Glu Glu 165 170 175 Gly Asp His Lys Leu Ser Trp Thr Leu Asp Ser Gln Leu Thr Pro Ser 180 185 190 Gly Gln Phe Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro Ser His 195 200 205 Arg Trp Met Leu Arg Cys Tyr Gly Ser Arg Arg His Ile Leu Gln Val 210 215 220 Trp Ser Glu Pro Ser Asp Leu Leu Glu Ile Pro Val Ser Gly Ala Ala 225 230 235 240 Asp Asn Leu Ser Pro Ser Gln Asn Lys Ser Asp Ser Gly Thr Ala Ser 245 250 255 His Leu Gln Asp Tyr Ala Val Glu Asn Leu Ile Arg Met Gly Met Ala 260 265 270 Gly Leu Ile Leu Val Val Leu Gly Ile Leu Ile Phe Gln Asp Trp His 275 280 285 Ser Gln Arg Ser Pro Gln Ala Ala Ala Gly Arg 290 295 <210> 358 <211> 481 <212> PRT <213> artificial sequence <220> <223> LILRA6(NP_001347096) <400> 358 Met Thr Pro Ala Leu Thr Ala Leu Leu Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr Arg Val Gln Ala Gly Pro Phe Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Ser Trp Gly Ser Pro Val Thr Ile Trp 35 40 45 Cys Gln Gly Ser Leu Glu Ala Gln Glu Tyr Gln Leu Asp Lys Glu Gly 50 55 60 Ser Pro Glu Pro Leu Asp Arg Asn Asn Pro Leu Glu Pro Lys Asn Lys 65 70 75 80 Ala Arg Phe Ser Ile Pro Ser Met Thr Gln His His Ala Gly Arg Tyr 85 90 95 Arg Cys His Tyr Tyr Ser Ser Ala Gly Trp Ser Glu Pro Ser Asp Pro 100 105 110 Leu Glu Leu Val Met Thr Gly Phe Tyr Asn Lys Pro Thr Leu Ser Ala 115 120 125 Leu Pro Ser Pro Val Val Ala Ser Gly Gly Asn Met Thr Leu Arg Cys 130 135 140 Gly Ser Gln Lys Gly Tyr His His Phe Val Leu Met Lys Glu Gly Glu 145 150 155 160 His Gln Leu Pro Arg Thr Leu Asp Ser Gln Gln Leu His Ser Gly Gly 165 170 175 Phe Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro Ser His Arg Trp 180 185 190 Arg Phe Thr Cys Tyr Tyr Tyr Tyr Thr Asn Thr Pro Arg Val Trp Ser 195 200 205 His Pro Ser Asp Pro Leu Glu Ile Leu Pro Ser Gly Val Ser Arg Lys 210 215 220 Pro Ser Leu Leu Thr Leu Gln Gly Pro Val Leu Ala Pro Gly Gln Ser 225 230 235 240 Leu Thr Leu Gln Cys Gly Ser Asp Val Gly Tyr Asp Arg Phe Val Leu 245 250 255 Tyr Lys Glu Gly Glu Arg Asp Phe Leu Gln Arg Pro Gly Gln Gln Pro 260 265 270 Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Pro 275 280 285 Ser His Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser Ser 290 295 300 Glu Trp Ser Ala Pro Ser Asp Pro Leu Asn Ile Leu Met Ala Gly Gln 305 310 315 320 Ile Tyr Asp Thr Val Ser Leu Ser Ala Gln Pro Gly Pro Thr Val Ala 325 330 335 Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Arg Gly Tyr Phe Asp 340 345 350 Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala His Pro Pro Leu Arg Leu 355 360 365 Arg Ser Met Tyr Gly Ala His Lys Tyr Gln Ala Glu Phe Pro Met Ser 370 375 380 Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser Tyr 385 390 395 400 Ser Ser Asn Pro His Leu Leu Ser Phe Pro Ser Glu Pro Leu Glu Leu 405 410 415 Met Val Ser Gly His Ser Gly Gly Ser Ser Leu Pro Pro Thr Gly Pro 420 425 430 Pro Ser Thr Pro Ala Ser His Ala Lys Asp Tyr Thr Val Glu Asn Leu 435 440 445 Ile Arg Met Gly Met Ala Gly Leu Val Leu Val Phe Leu Gly Ile Leu 450 455 460 Leu Phe Glu Ala Gln His Ser Gln Arg Asn Pro Gln Asp Ala Ala Gly 465 470 475 480 Arg <210> 359 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Human IgG1 Upper Hinge <400> 359 Glu Pro Lys Ser Cys Asp Lys Thr His Thr 1 5 10
Claims
1. An anti-LILRB1 antibody or an antigen-binding fragment thereof, wherein the anti-LILRB1 antibody or the antigen-binding fragment thereof comprises the following complementarity determining region (CDR): CDR-L1, wherein the amino acid sequence of CDR-L1 is shown in SEQ ID NO: 1, CDR-L2, wherein the amino acid sequence of CDR-L2 is shown in SEQ ID NO: 2, CDR-L3, wherein the amino acid sequence of CDR-L3 is shown in SEQ ID NO: 3, CDR-H1, wherein the amino acid sequence of CDR-H1 is shown in SEQ ID NO:4, CDR-H2, wherein the amino acid sequence of CDR-H2 is shown in SEQ ID NO:5, and CDR-H3, wherein the amino acid sequence of CDR-H3 is shown in SEQ ID NO:6, The CDRs are defined according to Kabat numbering.
2. The anti-LILRB1 antibody or antigen-binding fragment thereof according to claim 1, comprising: A light chain variable region, wherein the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 221 or 345, and The heavy chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:
222. 3 . The anti-LILRB1 antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody is a human IgG1 or IgG4 antibody.
4. The anti-LILRB1 antibody or antigen-binding fragment thereof according to claim 1, wherein the antigen-binding fragment is scFv, (scFv)2, Fab, Fab', F(ab')2, a fusion polypeptide comprising scFv fused to immunoglobulin Fc, or a fusion polypeptide comprising scFv fused to a light chain constant region. 5 . A pharmaceutical composition comprising the anti-LILRB1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier. 6 . A nucleic acid molecule encoding the anti-LILRB1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4 . A recombinant vector comprising the nucleic acid molecule according to claim 6 .
8. A recombinant cell, comprising the nucleic acid molecule according to claim 6 or the recombinant vector according to claim 7. 9 . A method for preparing an anti-LILRB1 antibody or an antigen-binding fragment thereof, the method comprising culturing the recombinant cell according to claim 8 .
Citation Information
Patent Citations
Novel hybrid promoter and recombinant vector which includes the promoter
KR101038126B1
Ethylene vinyl acetate copolymer and method for preparing the same
KR1020200061907A
Compositions and methods for inducing phagocytosis of MHC class i positive cells and countering Anti-CD47 / sirpa resistance
CA2959821A1
Targeted immunotolerance
CN110520436A
